Anti-α4β7 antibody

By developing anti-α4β7 antibodies, the interaction between α4β7 and its ligands is blocked and viral particles are internalized, solving the problem that existing treatments cannot effectively control HIV viral reservoirs and drug resistance, and achieving long-term viral load control.

CN115867352BActive Publication Date: 2026-11-17ABBVIE INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202180049613.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-07-16
Filing Date
2021-07-16
Publication Date
2026-11-17
Estimated Expiration
2041-07-16

AI Technical Summary

Technical Problem

Existing combination antiretroviral therapy (cART) is not effective in reducing the HIV latent viral reservoir, and treatments targeting viral proteins are prone to drug resistance. Therefore, a new method that can control viral load in the long term is needed.

Method used

Develop an anti-α4β7 antibody that specifically binds to human α4β7. By blocking the interaction between α4β7 and its ligand, it inhibits the co-stimulation of CD4+ T cells and viral transmission, and induces an immune response by internalizing viral particles through an Fc-dependent mechanism.

Benefits of technology

It effectively controls HIV replication and viral spread, reduces the risk of drug resistance, provides long-lasting viral load control, and avoids treatment failure due to high mutation frequency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115867352B_ABST
    Figure CN115867352B_ABST
Patent Text Reader

Abstract

This disclosure provides an anti-α4β7 antibody that binds to human α4β7, a method for its preparation, and its use in treating patients infected with HIV.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 1. Sequence List

[0002] This application contains a sequence list electronically submitted in ASCII format, the entire contents of which are incorporated herein by reference. The ASCII copy, created on July 14, 2021, is named 483WO_SL.txt and has a size of 106,797 bytes. 2. Technical Field

[0004] This application relates in particular to novel anti-α4β7 antibodies, polynucleotides encoding said antibodies, methods for their preparation, and methods for using these antibodies. 3. Background Technology

[0006] Today, more than 37 million people worldwide are living with the human immunodeficiency virus (HIV), and the prevalent population continues to grow. Significant progress has been made in controlling HIV with the advent of combination antiretroviral therapy (cART). People living with HIV need to take cART continuously throughout their lives. cART has risk-benefit limitations; furthermore, it does not reduce the HIV latent viral reservoir. There is a great need for improved treatment methods that can keep viral loads below detectable levels without requiring lifelong treatment.

[0007] In acute human HIV infection, high levels of viral replication and severe depletion of infected CD4+ T cells are considered to play a central role in the development of HIV-related immunodeficiency. α4β7 is an intestinal homing integrin expressed on T cells (CD4+ or CD8+), B cells, and other immune cells, and plays an important role in the pathogenesis of HIV infection. It has also been reported that α4β7 is integrated into the HIV envelope when viral particles germinate from infected host cells (Guzzo et al., *Sci. Immunol.*, 2017).

[0008] α4β7 integrin is a heterodimeric receptor expressed on T cell subsets, B cells, NK cells, and other immune cells. This integrin mediates lymphocyte transport to the gut-associated lymphoid tissue (GALT) by binding to its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), expressed on endothelial venules of the intestinal mucosa. Highly α4β7-expressing CD4+ T cells are targets of in vitro HIV infection (Cicala et al., *Proceedings of the National Academy of Sciences (PNAS)*, 2009), and are subsequently depleted during acute HIV infection (Sivro et al., *Science Transl Med*, 2018). α4β7 present in HIV-infected CD4+ cells and in HIV viral particles can mediate their transport to the GALT (Guzzo et al., *Science Immunology*, 2017). CD4+ T cells that home to GALTs account for the largest HIV reservoir in the body, even during antiretroviral therapy (Brenchley and Douek, Mucosal Immunol, 2008). 4. Summary of the Invention

[0010] This disclosure provides anti-α4β7 antibodies that specifically bind to human α4β7 and their binding fragments. The following detailed description provides the amino acid sequence of an exemplary CDR for an exemplary anti-α4β7 antibody, as well as the VH and VH of the heavy and light chains. L The amino acid sequence of the region.

[0011] This document provides a polynucleotide comprising a nucleotide sequence encoding the disclosed anti-α4β7 antibody, and a vector comprising the polynucleotide. Additionally, this document provides prokaryotic cells transformed with a vector comprising a nucleotide sequence encoding the disclosed anti-α4β7 antibody, eukaryotic cells transfected with the vector, and eukaryotic (e.g., mammalian) host cells engineered to express the nucleotide sequence. Methods for producing antibodies by culturing host cells and recovering the antibody are also provided.

[0012] This disclosure provides a method for treating a subject (e.g., a human subject) diagnosed with HIV infection with an anti-α4β7 antibody. The method generally involves administering to the subject an amount of the anti-α4β7 antibody described herein that effectively provides therapeutic benefit. The subject may be diagnosed with HIV infection in any clinical category.

[0013] Because the anti-α4β7 antibodies described in this article target human α4β7 rather than the viral protein, they provide an advantageous treatment method that does not induce HIV mutation-based resistance mechanisms that frequently occur in treatments targeting viral proteins due to the high mutation frequency of HIV.

[0014] Based on the data provided in this article, it is anticipated that the anti-α4β7 antibody described herein will provide therapeutic benefits to subjects diagnosed with HIV infection. 5. Description of the attached drawings

[0016] Figure 1 The mouse antibody Ab-m1 was shown to block the adhesion of HuT78 cells to MAdCAM-1.

[0017] Figure 2 Functional cross-reactivity of Ab-m1 to MAdCAM-1 in cynomolgus monkeys was demonstrated using a CHOK1-cα4β7 (cyno α4β7) cell adhesion assay.

[0018] Figure 3 This demonstrates that Ab-m1 blocks the binding of human MAdCAM-1 to primary human CD4+ memory T cells.

[0019] Figure 4 The binding of the mouse-human chimera Ab-c1 to human primary CD4+ memory T cells (human α4β7+CD4+CD45RO+) was demonstrated.

[0020] Figure 5 The binding of a biased, engineered humanized anti-α4β7 Ab-h1.9scFv clone against the human α4β7 antigen to yeast was demonstrated by flow cytometry. The clone Ab-h1.9(ae) exhibited binding similar to that of the parent Ab-h1.9.

[0021] Figures 6A to 6F This paper presents an analysis of α4β7 expression in samples from 45 HIV+ individuals and 10 healthy (HIV-) donors. The expression of α4β7 on CD4+ and CD8+ T cells (as measured by MESF) was compared between HIV+ and HIV-positive individuals. Only comparisons showing significant differences as determined by the Mann-Whitney two-tailed test are shown in the figure. T cell population abbreviations are: N+ = naive (CD28+CD45RO-), CM = central memory (CD28+CD45RO+CCR7+), TM = transient memory (CD28+CD45RO+CCR7-), EM = effector memory (CD28-CD45RO+), TE = terminal effector (CD28-CD45RO-); MESF = equivalent soluble fluorescent dye molecule.

[0022] Figures 7A to 7G-2 HIV viral particles captured using Ab-h1.9d-WT are shown. All tests were performed using a virus particle capture assay in bead form. Six laboratory-grown HIV strains were used. Figures 7A to 7FAb-h1.9d-WT was tested at 5 nM and 15 nM, while the negative control antibody was tested only at 15 nM. The amount of HIV p24 gag in the captured samples was shown as pg / mL in a 10 μL assay. Ab-h1.9d-WT was also tested with samples from two HIV-infected individuals, the samples having beads coated with 10 μg of antibody. Figure 7G-1 and Figure 7G-2 Input samples detected by digital droplet PCR ( Figure 7G-1 ) and captured samples ( Figure 7G-2 The amount of HIV gag RNA in the sample is shown as copies / mL.

[0023] Figures 8A to 8E Immune complexes (HIV viral particles with different antibodies) binding to FcγR are shown. Immune complexes were first formed by incubating antibodies (Ab-h1.9d-WT, Ab-h1.9d with a LALA mutation to significantly reduce FcγR binding, Ab-Vedo, and an isotype negative control) with HIV NL4-3, and then captured onto FcγR immobilized on a plate. FcγRI and FcγRIIIa (V158) were captured on a nickel plate, while FcγRIIa (H131), FcγRIIa (R131), and FcγRIIIa (F158) were captured on a neutral avidin plate to increase detection sensitivity. The amount of HIV p24 gag detected is shown as pg / mL in a 10 μL assay. Results of representative experiments are shown.

[0024] Figures 9A to 9C The α4β7 and Fc-dependent uptake of α4β7-coated beads in Ab-h1.9d-WT-mediated THP-1 cells is shown. Phagocytosis scores of immune complexes (containing α4β7-coated beads and specified anti-α4β7 or control antibodies) in THP-1 cells treated with the complex for 3 hours are plotted. Figure 9A Data from a representative experiment is shown. Figure 9B Normalized data from three independent experiments are shown. Significance was determined using one-way ANOVA in conjunction with Tukey's multiple comparisons test. ****p<0.0001, ***p=0.0001-0.001, **p=0.001-0.01, *p=0.01-0.05, ns≥0.05. Figure 9C Representative images of cells treated with the Ab-h1.9d-WT immune complex and three types of internalized α4β7-coated beads, obtained by imaging cytometer, are shown.

[0025] Figure 10The binding of the anti-α4β7 antibody to α4β7+GFP+VLP (virus-like particles) is shown. The binding of the antibody to the VLP was determined using ELISA. Ab-h1.9d-WT, Ab-h1.9d-LALA, and Ab-Vedo bound to the α4β7+GFP+VLP with similar EC50 values. Representative data from two independent experiments are shown.

[0026] Figures 11A to 11B This study demonstrates the α4β7 and Fc dependence of Ab-h1.9d-WT-mediated uptake of α4β7+GFP+VLP (virus-like particles) in THP-1 cells. Figure 11A The uptake of α4β7+GFP+VLP by THP-1 cells as a percentage of GFP+ cells, as measured by flow cytometry, is shown. Figure 11B This study demonstrates the inhibitory effect of Lat A (Lat A) on α4β7+GFP+VLP uptake by the red sea sponge. For Figure 11B THP-1 cells were pretreated with Lat A for 2 hours, and then... Figure 11A Incubate with VLP and antibody as described above. Figures 11A to 11B The mean ± standard deviation shown are derived from the combined results of 4 and 3 independent experiments, respectively. Significance (****) p =5.4x10 -5 The result was calculated using a two-tailed Student's t-test, where... p <0.05 is considered significant.

[0027] Figures 12A to 12B This demonstrates the inhibition of the interaction between HIV gp120 and α4β7 by different antibodies. Figure 12A This demonstrates the binding of RPMI 8866 cells to the HIV gp120-V2 WT peptide, but not the control peptide. RPMI 8866 cells constitutively express α4β7 on their cell surface. The HIV gp120 V2 WT peptide and the HIV gp120 V2 control peptide are sequence identical, but the control peptide contains a mutation in four amino acids that mediate the binding of α4β7 to gp120. Figure 12B The study demonstrated the inhibition of the binding of different antibodies to the HIV gp120-V2 WT peptide and RPMI 8866 cells expressing α4β7. Ab-h1.9d-WT was more effective than Ab-Vedo in inhibiting the binding of the HIV gp120-V2 WT peptide to RPMI 8866 cells expressing α4β7.

[0028] Figure 13The percentages of human and cynomolgus monkey CD4+ and CD8+ T cell subsets bound by Ab-h1.9d-WT are shown. The binding of Ab-h1.9d-WT to human and cynomolgus monkey CD4+ and CD8+ T cells was assessed by flow cytometry. The percentage of α4β7+ T cell subsets bound by Ab-h1.9d-WT was determined. Data were obtained from 3 human and 5 cynomolgus monkey donors.

[0029] Figures 14A to 14F This demonstrates the binding specificity of Ab-h1.9d-WT to various integrins. In the expression of human ( Figure 14A , Figure 14C and Figure 14E ) or cynomolgus monkey integrin ( Figure 14B , Figure 14D and Figure 14F The binding specificity of Ab-h1.9d-WT was evaluated on recombinant cells. It was also evaluated for its binding with α4β1 (…). Figure 14C / Figure 14D ) and αEβ7 ( Figure 14E / Figure 14F Compared to integrins, targeting integrin α4β7 ( Figure 14A / Figure 14B The binding of Ab-Naa and etretinate-derived Ab-Etro was used as positive controls for α4 and β7 integrin specificity, respectively, while Ab-Ctet was used as an isotype control. FACS binding results are expressed as MFI of titrated mAbs. N = 1.

[0030] Figure 15 The nonspecific binding of Ab-h1.9d-WT to HEK293 cells was evaluated using flow cytometry. At a test concentration of 100 μg / mL, the positive control showed high binding, while negligible binding was observed against both Ab-h1.9d-WT and the isotype control Ab-cTet. The percentage of HEK293 cells binding to test mAb(A) and the MFI of binding strength to test mAb(B) are presented. N = 2.

[0031] Figures 16A to 16B The internalization of the α4β7 complex with Ab-h1.9d-WT or Ab-Vedo in human primary cells is shown. Figure 16A The internalization of Ab-h1.9d-WT in naïve CD4+ T and CD8+ T cells from human peripheral blood donors is shown. Scatter plots from both donors indicate the percentage of α4β7 cells treated with Ab-h1.9d-WT at 4 or 37°C 18 hours post-treatment. Residual α4β7 cells on the cell surface were detected using Alexa-647-labeled anti-β7 Ab-Etro. Figure 16BThe quantification of α4β7 internalization in a subset of T cells treated with Ab-h1.9d-WT is shown (as opposed to the reduced expression of surface α4β7 observed after treatment at 4°C). (N = two donors). Initial cells were defined as CD45RA+.

[0032] Figures 17A to 17B This demonstrates that Ab-h1.9d-WT blocks MAdCAM-1 co-stimulatory signaling on primary human CD4+ T cells. For Figure 17A Flow cytometry analysis was used to measure the activation of human primary CD4+ T cells by anti-CD3 and MAdCAM-1 in the presence of allotype controls Ab and Ab-h1.9d-WT as the percentage of Ki67+CD25+ cells (Ki67+ on the X-axis, CD25+ on the Y-axis). Data were obtained from representative donors. Figure 17B The activation of human primary CD4+ T cells by anti-CD3 and MAdCAM-1 in the presence of isotype controls Ab, Ab-h1.9d-WT, and Ab-Vedo was measured as the percentage of Ki67+CD25+ cells (on the Y-axis). Data were obtained from 6 healthy donors. Statistical analysis was performed using a paired t-test with two tails: **P<0.01, ****P<0.0001).

[0033] Figure 18 This study demonstrates that Ab-h1.9d-WT does not block VCAM-1-mediated cell adhesion. The blocking effect of Ab-h1.9d-WT on VCAM-1 cell adhesion was determined using a HuT78 cell adhesion assay. Ab-Nata (anti-α4mAb) was used as a positive control, and Ab-cTet as a negative control. Representative data are shown, where reduced luminescence (RLU) indicates decreased cell binding due to ligand blockade. N = 3.

[0034] Figures 19A to 19B The binding of Ab-h1.9d-WT to cells expressing human FcγR was demonstrated by flow cytometry compared to Ab-Vedo. Ab-h1.9d-WT was analyzed using engineered CHO-K1 cells expressing various cell surface human FcγRs. Figure 19A ) and Ab-Vedo ( Figure 19B The binding of ) to human FcγR is expressed as the geometric mean of fluorescence. N = 1.

[0035] Figures 20A to 20B The reporter gene-based ADCC and ADCP activities of Ab-h1.9d-WT were demonstrated. The ability of Ab-h1.9d-WT to induce Fc-mediated in vitro ADCC and ADCP activities was evaluated using a reporter gene assay. Figure 20AADCC activity was assessed using engineered Jurkat human FcγR IIIa V158+ effector reporter cells and RPMI 8866 target cells; N=2. Figure 20B ADCP activity was measured using engineered Jurkat human FcγRIIa H131+ effector reporter cells and RPMI 8866 target cells; N=2. Ab-Ritu was used as a positive control in the assay. Results are expressed as luminescence (RLU); high signal indicates ADCC and ADCP activity.

[0036] Figure 21 The CDC activity of Ab-h1.9d-WT is shown. The ability of Ab-h1.9d-WT to induce Fc-mediated in vitro CDC activity was evaluated using RPMI 8866 target cells and human serum as complement factor sources; N = 2 donor sera for testing. Ab-Ritu was used as a positive control. Results are expressed as percentage of cell killing; higher cell killing indicates CDC activity.

[0037] Figure 22 The cytotoxic ADCC activity of Ab-h1.9d-WT is demonstrated. In a FACS-based cytotoxicity assay, the ability of Ab-h1.9d-WT to induce Fc-mediated in vitro ADCC was evaluated using HuT78 cells as target cells and primary human NK cells from two donors as effector cells. Target cell killing (cytotoxicity) is expressed as the percentage of ADCC against both donors. 6. Detailed Implementation Methods

[0039] Without being bound by theory, it is assumed that embodiments of the present invention exert viral control against HIV infection through two main mechanisms of action: 1) a Fab-dependent mechanism: blocking the interaction between α4β7 and its ligands such as MAdCAM-1 and HIV gp120, thereby preventing co-stimulation of CD4+ T cells mediated by the signal transduction of these ligands, and inhibiting HIV replication in these stimulated cells (Nawaz et al., *Mucosal Immunology* 2018; Livia et al., *Proceedings of the National Academy of Sciences* 2020), HIV infection in intestinal tissue (Guzzo et al., *Science Immunology* 2017), and cell-to-cell viral transmission (Arthos et al., *Nature Immunology* 2008); and 2) an Fc-dependent mechanism: inducing a “vaccination effect” in which anti-α4β7 mAb binds to α4β7+ HIV viral particles to form an immune complex, which is transmitted through mAb... The Fc domain interacts with FcγR on antigen-presenting cells (APCs) and is internalized and processed, and the resulting viral peptide is then presented on the surface of the APC to elicit a novel and durable HIV-specific immune response to suppress viral replication (Parsons et al., Retrovirology, 2018; Naranjo-Gomez et al., Curr. Opin. HIV AIDS, 2019).

[0040] α4β7 integrin is normally in a quiescent (inactive) state with low affinity for its ligands. Once activated, it can bind to its ligands (e.g., MAdCAM-1 and gp120) with high affinity (Ye et al., *Blood*, 2012; Lertjuthaporn et al., *PLOS One*, 2018). During HIV infection, the motif in the V2 region of HIV gp120 mimics MAdCAM-1 and is able to bind α4β7 (Peachman et al., *PLOS One*, 2015). The interaction between α4β7 and gp120 induces activation of lymphocyte function-associated antigen-1 (LFA-1), potentially inducing the formation of virological synapses and thus enhancing HIV intercellular transmission (Arthos et al., *Nature Immunology*, 2008). Intercellular transmission is crucial for facilitating viral spread in tissues and is more important for viral delivery than for cell-free viruses. When combined with α4β7, embodiments of the present invention can reduce α4β7-mediated HIV intercellular transmission by disrupting the interaction between α4β7 and gp120, thereby inducing the internalization of the α4β7 antibody-binding complex into cells, or by inactivating α4β7. Therefore, embodiments of the present invention demonstrate the ability to inhibit HIV replication and viral spread in tissues.

[0041] By targeting human protein α4β7 instead of viral proteins, embodiments of the present invention do not induce viral resistance mutations that are typically associated with treatments targeting viral proteins due to the high mutation frequency of HIV.

[0042] 6.1. Abbreviations

[0043] In many embodiments, the antibodies described herein are described by their respective polypeptide sequences. Unless otherwise stated, the polypeptide sequences are provided in the N→C orientation.

[0044] In many embodiments, the polynucleotides described herein are described by their respective polynucleotide sequences. Unless otherwise stated, the polynucleotide sequences are oriented 5′→3′.

[0045] For polypeptide sequences, conventional three- or single-letter abbreviations of genetically encoded amino acids can be used, as shown in Table 1 below.

[0046]

[0047] Some sequences are defined by structural formulas specifying amino acid residues belonging to certain categories (e.g., aliphatic, hydrophobic, etc.). Table 2 below indicates the various categories to which the genetically encoded amino acids used in this paper belong. Some amino acids may belong to more than one category. Cysteine ​​containing a thiol group and conformationally restricted proline are not specified in any category.

[0048]

[0049] The abbreviations used in the various exemplary embodiments include those provided in Table 3 below:

[0050]

[0051]

[0052]

[0053] 6.2. Definition

[0054] Unless otherwise defined herein, scientific and technical terms used in conjunction with this disclosure have the meanings commonly understood by one of ordinary skill in the art.

[0055] As used herein, unless otherwise stated, the numbering of antibody amino acid residues follows the EU numbering scheme.

[0056] 6.3. Anti-α4β7 antibody

[0057] In one aspect, this disclosure relates to antibodies that specifically bind to the α4β7 heterodimeric integrin receptor (also known as a4b7, LPAM-1, lymphocyte Pierre node adhesion molecule 1, and a dimer of integrin α-4 and integrin β-7).

[0058] As used herein, the term "antibody" (Ab) refers to an immunoglobulin molecule that specifically binds to a particular antigen, such as α4β7. In some embodiments, the anti-α4β7 antibody of this disclosure binds to human α4β7 and thereby modulates the immune system. The anti-α4β7 antibody of this disclosure contains complementarity-determining regions (CDRs), also known as hypervariable regions, in both the light and heavy chain variable domains. The more conserved portion of the variable domain is called the backbone (FR). As is known in the art, the amino acid positions / boundaries depicting the antibody hypervariable regions can vary depending on the context and various definitions known in the art. Some positions within the variable domain can be considered heterozygous hypervariable positions because these positions can be considered within the hypervariable region under one set of criteria and outside the hypervariable region under different sets of criteria. One or more of these positions can also be found in extended hypervariable regions. This disclosure provides antibodies containing alterations at these heterozygous hypervariable positions. The variable domains of the natural heavy and light chains each contain four FR regions, primarily by adopting a β-sheet configuration, linked by three CDRs that form loop links and, in some cases, form part of a β-sheet structure. CDRs in each chain are tightly bound together via FR regions and utilize CDRs from the other chain to help form the target binding site of the antibody. See Kabat et al., Sequences of Immune Target Proteins (National Institute of Health, Bethesda, MD, 1987).

[0059] The antibodies disclosed herein may be polyclonal, monoclonal, genetically engineered, and / or otherwise modified in nature, including but not limited to chimeric antibodies, humanized antibodies, human antibodies, single-chain antibodies, etc. In various embodiments, the antibody comprises all or a portion of its constant region. In some embodiments, the constant region is selected from isotypes such as IgA (e.g., IgA1 or IgA2), IgD, IgE, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), and IgM. In a specific embodiment, the anti-α4β7 antibody described herein comprises IgG1. In other embodiments, the anti-α4β7 antibody comprises IgG2. In other embodiments, the anti-α4β7 antibody comprises IgG4. As used herein, the “constant region” of an antibody includes a natural constant region, an allotype, or a variant, such as any one of T250Q, L234A, L235A, D356E, L358M, M428L, and / or A431G in human IgG1.

[0060] The light chain constant region of the anti-α4β7 antibody can be a carpa (κ) light chain region or a lamuda (λ) region. The λ light chain region can be any known subtype, such as λ1, λ2, λ3, or λ4. In some embodiments, the anti-α4β7 antibody comprises a carpa (κ) light chain region.

[0061] As used herein, the term "monoclonal antibody" is not limited to antibodies produced by hybridoma technology. A monoclonal antibody is derived from a single clone by any method available or known in the art, including any eukaryotic, prokaryotic, or phage clone. A variety of techniques known in the art may be used, including the use of hybridomas, recombinant monoclonal antibodies, including the use of hybridomas, recombinant and phage display technologies, or combinations thereof.

[0062] As used in this article, the term "chimeric" antibody refers to an antibody having a variable sequence derived from a non-human immunoglobulin (e.g., rat or mouse antibody) and a constant region of a human immunoglobulin (typically selected from a human immunoglobulin template).

[0063] The “humanized” form of a non-human (e.g., mouse) antibody comprises all of at least one, typically two, variable domains, wherein all or substantially all of the CDR regions correspond to those CDR regions of the non-human immunoglobulin, and all or substantially all of the FR regions are those FR regions in the human immunoglobulin sequence. Humanized antibodies may also comprise at least a portion of the immunoglobulin constant region (Fc), typically a portion of the common sequence of human immunoglobulins.

[0064] "Human antibodies" include antibodies having the amino acid sequence of human immunoglobulins, and include antibodies isolated from human immunoglobulin libraries or from animals that are transgenic against one or more human immunoglobulins and do not express endogenous functional immunoglobulins. Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences.

[0065] The disclosed anti-α4β7 antibody comprises a full-length (complete) antibody molecule.

[0066] Anti-α4β7 antibodies can be antibodies whose sequences have been modified to alter the function of at least one constant region-mediated biological effector. For example, in some embodiments, anti-α4β7 antibodies are modified to reduce the function of at least one constant region-mediated biological effector relative to unmodified antibodies, such as reducing binding to one or more Fc receptors (FcγRs) such as FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and / or FcγRIIIb. FcγR binding can be reduced by mutating a segment of the immunoglobulin constant region of the antibody in a specific region necessary for FcγR interaction (see, e.g., Canfield and Morrison, 1991, J. Exp. Med. 173: 1483-1491; and Lund et al., 1991, J. Immunol. 147: 2657-2662). Reduced antibody FcγR binding capacity can also impair the function of other effectors that depend on FcγR interactions, such as opsonization, phagocytosis, and antigen-dependent cytotoxicity (“ADCC”).

[0067] The anti-α4β7 antibodies described herein include antibodies that have been modified relative to unmodified antibodies to acquire or improve the function of at least one constant region-mediated biological effector (e.g., enhanced FcγR interaction) (see, for example, U.S. Patent Application No. 2006 / 0134709). For example, the anti-α4β7 antibodies of this disclosure may have constant regions that bind FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and / or FcγRIIIb with greater affinity than the corresponding unmodified constant regions.

[0068] Other substitutions that can alter the FcγR binding and / or ADCC effector function of anti-α4β7 antibodies include K322A substitution or L234A and L235A double substitution in the Fc region. See, for example, Hezareh et al., Journal of Virology, 75(24): 12161-12168 (2001).

[0069] The anti-α4β7 antibody disclosed herein may comprise a modified (or variant) CH2 domain or an intact Fc domain, the modified (or variant) CH2 domain or the intact Fc domain comprising amino acid substitutions that increase binding to FcγRIIb and / or decrease binding to FcγRIIIa compared to binding to the corresponding wild-type CH2 or Fc region. The variant CH2 or variant Fc domain may include one or more substitutions at positions 263, 266, 273, and 305. In some embodiments, relative to the wild-type CH2 domain, the anti-α4β7 antibody comprises one or more substitutions selected from V263L, V266L, V273C, V273E, V273F, V273L, V273M, V273S, V273Y, V305K, and V305W.

[0070] Other examples of variant CH2 or variant Fc domains that can increase binding to FcγRIIb and / or decrease binding to FcγRIIIa compared to the corresponding wild-type CH2 or Fc domains include those found in the literature “Vonderheide et al., Cancer Res., 19(5), 1035-1043 (2013)”, such as S267E or S267E / L328F in human IgG1.

[0071] Anti-α4β7 antibodies containing the constant region of human IgG4 can contain the S228P mutation, which has been reported to prevent Fab arm exchange. See, for example, Silva, JP et al., Journal of Biological Chemistry, 290(9), 5462-5469 (2015).

[0072] In some embodiments, the anti-α4β7 antibody comprises altering its binding affinity to the fetal Fc receptor FcRn, for example, by mutating a segment of the immunoglobulin constant region at a specific region involved in FcRn interaction. In a particular embodiment, the IgG class of anti-α4β7 antibody is mutated such that at least one of amino acid residues 250, 314, and 428 in the heavy chain constant region is substituted individually or in any combination thereof. For position 250, the substituted amino acid residue can be any amino acid residue other than threonine, including but not limited to alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, valine, tryptophan, or tyrosine. For position 314, the substituted amino acid residue can be any amino acid residue other than leucine, including but not limited to alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. For position 428, the substituted amino acid residue can be any amino acid residue other than methionine, including but not limited to alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. An exemplary substitution known to alter the function of the Fc effector is the Fc substitution M428L, which can be combined with the Fc substitution T250Q. Other specific combinations of suitable amino acid substitutions are identified in Table 1 of U.S. Patent No. 7,217,797. Such mutations increase binding to FcRn, which protects the antibody from degradation and increases its half-life.

[0073] Anti-α4β7 antibodies with high affinity for human α4β7 may be ideal for therapeutic and diagnostic uses. Therefore, this disclosure contemplates antibodies with high binding affinity for human α4β7. In specific embodiments, the anti-α4β7 antibody binds human α4β7 with an affinity of at least about 100 nM, but may exhibit higher affinity, such as at least about 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.1 nM, 0.01 nM, or even higher. In some embodiments, the antibody binds human α4β7 with an affinity in the range of about 1 pM to about 10 nM, about 100 pM to about 10 nM, about 100 pM to about 1 nM, or an affinity in the range between any of the foregoing values.

[0074] The affinity of anti-α4β7 antibodies for human α4β7 can be determined using techniques well known in the art or described herein, such as, but not limited to, ELISA, isothermal titration calorimetry (ITC), surface plasmon resonance, or fluorescence polarization assays.

[0075] Anti-α4β7 antibodies generally consist of heavy and light chains. The heavy chain contains three molecules (in N→C order) referred to in this paper as V. H CDR#1, V H CDR#2 and V H The variable region (V) of the complementary determinant region (“CDR”) of CDR#3 H The light chain contains three components referred to in this paper (in N→C order) as V. L CDR#1, V L CDR#2 and V L The variable region (V) of the complementarity determination region in CDR#3 L This article provides an exemplary amino acid sequence of CDR, as well as exemplary V-chains of the heavy and light chains against α4β7. H and V L The amino acid sequence. Specific embodiments of anti-α4β7 antibodies include these exemplary CDRs and / or V. H and / or V L The sequence, and antibodies that compete with such antibodies for binding to human α4β7.

[0076] In some embodiments, the anti-α4β7 antibody is suitable for administration to humans. In a specific embodiment, the anti-α4β7 antibody is humanized.

[0077] In some embodiments, the amino acid sequence of the CDR of the anti-α4β7 antibody is selected from the sequences in Table 4.

[0078]

[0079] Specific exemplary embodiments of anti-α4β7 antibodies having the above-described CDRs are described herein. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, and SEQ ID NO: 67. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 77. In some embodiments, the anti-α4β7 antibody has the CDRs of SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, and SEQ ID NO: 87.

[0080] In some embodiments, the anti-α4β7 antibody comprises V sequences selected from those in Table 5. H Chain and V L chain:

[0081]

[0082] In some embodiments, the anti-α4β7 antibody comprises V, which corresponds to the sequence in SEQ ID NO: 10. H The chain; and the V corresponding to SEQ ID NO: 11 in the sequence. LIn some embodiments, the anti-α4β7 antibody comprises a V sequence corresponding to any one of SEQ ID NO: 20 or SEQ ID NO: 22 to SEQ ID NO: 23. H The chain and the V that corresponds in sequence to any one of SEQ ID NO: 25 or SEQ ID NO: 27 to SEQ ID NO: 28 L Chain. In some embodiments, the anti-α4β7 antibody comprises a V sequence corresponding to the variant of SEQ ID NO: 21. H The chain; and the V corresponding in sequence to the variant of SEQ ID NO: 26. L In some embodiments, the anti-α4β7 antibody comprises V, which corresponds to the sequence in SEQ ID NO: 40. H The chain; and the V corresponding to SEQ ID NO: 41 in the sequence. L In some embodiments, the anti-α4β7 antibody comprises V, which corresponds to SEQ ID NO: 50 in sequence. H The chain; and the V corresponding to SEQ ID NO: 51 in the sequence. L In some embodiments, the anti-α4β7 antibody comprises V, which corresponds to the sequence in SEQ ID NO: 60. H The chain; and the VL chain corresponding to SEQ ID NO: 61 in sequence. In some embodiments, the anti-α4β7 antibody comprises the VL chain corresponding to SEQ ID NO: 70 in sequence. H The chain; and the V corresponding to SEQ ID NO: 71 in the sequence. L In some embodiments, the anti-α4β7 antibody comprises V, which corresponds to the sequence in SEQ ID NO: 80. H The chain; and the V corresponding to SEQ ID NO: 81 in the sequence. L chain.

[0083] Those skilled in the art will understand that the V in the anti-α4β7 antibody described herein H or V L Certain mutations in the sequence can provide anti-α4β7 antibodies within the scope of this disclosure. Mutations may include the V disclosed herein. H or V L Amino acid substitutions, additions, or deletions in the sequence can be made while retaining significant anti-α4β7 activity. Therefore, in some embodiments, the anti-α4β7 antibody comprises V... H V sequences having at least 85%, at least 90%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. HSequence. Anti-α4β7 antibodies may contain V sequences similar to those of any of the antibodies shown in Table 5. H The sequence compared to V with up to 8, up to 7, up to 6, up to 5, up to 4, up to 3, or up to 2 mutations. H Sequence. In some embodiments, the anti-α4β7 antibody may contain a V sequence similar to any of the antibodies shown in Table 5. H The sequence compared to V with 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer mutations. H Sequence. In some embodiments, the anti-α4β7 antibody comprises V with a single amino acid substitution. H Sequence. In some embodiments, V H The mutation in the sequence is located in V H CDR#1, V H CDR#2 or V H In CDR#3. In some embodiments, the anti-α4β7 antibody comprises V as shown in Table 5. L V sequences having at least 85%, at least 90%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. L Sequence. Anti-α4β7 antibodies may contain V sequences similar to those of any of the antibodies shown in Table 5. L The sequence compared to V with up to 8, up to 7, up to 6, up to 5, up to 4, up to 3, or up to 2 mutations. L Sequence. In some embodiments, the anti-α4β7 antibody may contain a V sequence similar to any of the antibodies shown in Table 5. L The sequence is compared to V with 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer mutations. L Sequence. In some embodiments, the anti-α4β7 antibody comprises V with a single amino acid substitution. L Sequence. In some embodiments, V L The mutation in the sequence is located at VL CDR#1, VL CDR#2, or VLCDR#3.

[0084] In some embodiments, the anti-α4β7 antibody comprises a heavy chain amino acid sequence and / or a light chain amino acid sequence selected from the sequences in Table 6.

[0085]

[0086] In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 90 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 92 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 94 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 96 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 98 and a light chain corresponding to SEQ ID NO: 100.

[0087] Post-translational modifications to the anti-α4β7 antibody sequence can occur, such as the cleavage of one or more (e.g., 1, 2, 3 or more) amino acid residues at the C-terminus of the antibody heavy chain, resulting in a truncated form.

[0088] In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 91 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 93 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 95 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 97 and a light chain corresponding to SEQ ID NO: 100. In some embodiments, the anti-α4β7 antibody comprises a heavy chain corresponding to SEQ ID NO: 99 and a light chain corresponding to SEQ ID NO: 100.

[0089] In some embodiments, the anti-α4β7 antibody competes with a reference antibody for binding to human α4β7 in an in vitro assay. In some embodiments, the anti-α4β7 antibody competitively binds to human α4β7 on cells expressing human α4β7. The reference antibody may be any of the anti-α4β7 antibodies described herein. In some embodiments, the reference antibody is an antibody provided in Tables 4 through 6. In some embodiments, the reference antibody is an antibody provided in Table 8. In specific embodiments, the reference antibody is selected from research-grade antibodies, such as vedolizumab, generated using an amino acid sequence derived from an anti-human α4β7 antibody or an antibody having an equivalent amino acid sequence thereto.

[0090] In some embodiments, the anti-α4β7 antibody antagonizes (e.g., inhibits) a human α4β7 heterodimer containing an α4 (SEQ ID NO: 1 to SEQ ID NO: 2) and a β7 (SEQ ID NO: 3 to SEQ ID NO: 4). α4β7 receptor antagonism can occur through a variety of mechanisms, such as by inhibiting α4β7 binding via at least one of its ligands, such as human MAdCAM-1 (SEQ ID NO: 5) or human VCAM-1 (SEQ ID NO: 6).

[0091] The anti-α4β7 antibody described herein binds to human α4β7. Cross-reactivity of antibodies binding to α4β7 from other species (e.g., from monkeys, such as cynomolgus monkeys) can provide advantages, such as the ability to test biological activity in monkey animal models. Such animal model testing can be used to screen anti-α4β7 antibodies for efficacy-related properties, such as favorable pharmacokinetics, or safety-related properties, such as reduced hepatotoxicity. In some embodiments, the anti-α4β7 antibody binds to both cynomolgus monkey α4β7 and human α4β7.

[0092] Competitive assays include, but are not limited to, radiolabeled immunosorbent assays (RIA), enzyme-linked immunosorbent assays (ELISA), sandwich ELISA, fluorescence activated cell sorting (FACS) assays, and surface plasmon resonance assays.

[0093] In antibody competition assays between a reference antibody and a test antibody (regardless of species or isotype), the reference antibody can first be labeled with a detectable marker such as a fluorophore, biotin, or enzyme (or even a radioactive) marker to facilitate subsequent identification. In this case, cells expressing human α4β7 are incubated with an unlabeled test antibody, the labeled reference antibody is added, and the intensity of the bound marker is measured. If the test antibody competes with the labeled reference antibody by binding to an overlapping epitope, the intensity will be reduced compared to a control reaction without the test antibody.

[0094] In a specific embodiment of this experiment, the concentration of the labeled reference antibody that produces 80% of the maximum binding under experimental conditions (e.g., a specific cell density) is first determined. 80% Then use 10X concentration. 80% Unlabeled test antibodies and concentrations 80% A competitive assay was conducted using a labeled reference antibody.

[0095] Inhibition can be expressed as the inhibition constant or K. i It is calculated according to the following formula:

[0096] K i =IC 50 / (1+[reference Ab concentration] / K) d ),

[0097] IC 50 This is the concentration of the test antibody that reduces the binding of the reference antibody by 50%, and K d This is the dissociation constant of the reference antibody, a measure of its affinity for human α4β7. Antibodies competing with the anti-α4β7 antibody disclosed herein can have a Kc of 10 pM to 10 nM under the experimental conditions described herein. i .

[0098] In various embodiments, under the specific test conditions used, at a reference antibody concentration of 80% of the maximum binding and a test antibody concentration 10 times higher than the reference antibody concentration, if the test antibody reduces the binding of the reference antibody by at least about 20% or more, such as at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or even more, or reduces it by a percentage between any of the foregoing values, then the test antibody is considered to compete with the reference antibody.

[0099] Another aspect of this disclosure includes anti-α4β7 antibody-binding fragments capable of specifically binding to human α4β7. In some embodiments, these anti-α4β7 binding fragments comprise at least one and up to all of the anti-α4β7 antibodies disclosed herein, using a CDR. Examples of antibody-binding fragments include, but are not limited to, Fab, Fab′, F(ab′)2, Fv fragments, single-chain Fv fragments, and single-domain fragments.

[0100] Anti-α4β7 antibodies or their binding fragments may have one or more amino acids inserted into one or more of their CDRs, for example as described in the following literature: Jung and Plückthun, 1997, Protein Engineering 10:9, 959-966; Yazaki et al., 2004, Protein Engineering Design and Selection 17(5):481-9. Published online on August 17, 2004; and U.S. Patent Application No. 2007 / 0280931.

[0101] 6.4. Polynucleotides encoding anti-α4β7 antibodies, expression systems, and methods for antibody preparation

[0102] This disclosure includes a polynucleotide molecule encoding the light and heavy chain genes of an immunoglobulin that is anti-α4β7 antibody, a vector containing such polynucleotide, and a host cell capable of producing the anti-α4β7 antibody of this disclosure.

[0103] The anti-α4β7 antibody of this disclosure can be prepared by recombinant expression of immunoglobulin light and heavy chain genes in host cells. To recombinantly express the antibody, host cells are transfected with one or more recombinant expression vectors carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibody, thereby expressing the light and heavy chains in the host cells and optionally secreting them into a culture medium from which the antibody can be recovered.

[0104] To generate polynucleotides encoding this type of anti-α4β7 antibody, DNA fragments encoding the variable regions of the light and heavy chains are first obtained. These DNA fragments can be obtained by amplifying and modifying germline DNA or cDNA encoding the variable sequences of the light and heavy chains, for example, using polymerase chain reaction (PCR).

[0105] Once the V encoding the anti-α4β7 antibody is obtained... H and V L These DNA fragments can be further manipulated using conventional recombinant DNA techniques, such as converting variable region genes into full-length antibody chain genes, Fab fragment genes, or scFv genes. In these manipulations, the gene encoding V... L or V H A DNA fragment can be operatively linked to another DNA fragment encoding a different protein, such as an antibody constant region or a flexible linker. The term "operatively linked" as used herein refers to linking two DNA fragments such that the amino acid sequences encoded by the two fragments remain in frame of reference.

[0106] By encoding V HThe DNA can be operatively linked to another DNA molecule encoding the heavy chain constant region (CH1, CH2, CH3, and optional CH4), allowing the isolated V-coding DNA to be transferred to the target region. H The DNA in the region is converted into a full-length heavy chain gene. The sequences of human heavy chain constant region genes are known in the art (see, for example, Kabat, E.A. et al., 1991, Sequences of Proteins of Immunological Interest, 5th Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242), and DNA fragments containing these regions can be obtained by routine PCR amplification. Heavy chain constant regions can be IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant regions, but in some embodiments are IgG1 or IgG4. For Fab fragment heavy chain genes, the region encoding V... H The DNA can be operatively linked to another DNA molecule that encodes only the heavy chain CH1 constant region.

[0107] By encoding V L The DNA can be operatively linked to another DNA molecule encoding the light chain constant region CL, which can encode V. L The isolated DNA from the regions is converted into full-length light chain genes (as well as Fab light chain genes). The sequences of human light chain constant region genes are known in the art (see, for example, Kabat et al., 1991, Protein Sequences of Immunological Significance, 5th Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments containing these regions can be obtained by routine PCR amplification. Light chain constant regions can be κ or λ constant regions, but in some embodiments are κ constant regions.

[0108] To express the anti-α4β7 antibody of this disclosure, DNA encoding partial or full-length light and heavy chains, obtained as described above, is inserted into an expression vector such that the gene is operatively linked to transcriptional and translational control sequences. Hereinafter, the term "operatively linked" means linking the antibody gene to a vector such that the transcriptional and translational control sequences within the vector perform their intended functions of regulating antibody gene transcription and translation. The expression vector and expression control sequences are selected to be compatible with the host cells used for expression. The antibody light chain gene and antibody heavy chain gene can be inserted into separate vectors, or more commonly, both genes can be inserted into the same expression vector.

[0109] The antibody gene is inserted into the expression vector using conventional methods (e.g., ligating the antibody gene fragment to a complementary restriction site on the vector, or blunt-end ligation if no restriction site is present). The expression vector may already carry the antibody constant region sequence before inserting the light or heavy chain sequence associated with the anti-α4β7 antibody. For example, a vector containing a V-type antibody associated with an anti-α4β7 monoclonal antibody... H and V L The method to convert the sequences into full-length antibody genes is to insert them separately into expression vectors that already encode the heavy chain constant region and the light chain constant region, so that V H The segment is operatively connected to the CH segment within the carrier, while the V segment... L The segment is operatively linked to the CL segment within the vector. Alternatively or additionally, the recombinant expression vector may encode a signal peptide that promotes the secretion of the antibody chain from the host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked to the amino terminus of the antibody chain gene in a reading frame-aligned manner. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide derived from a non-immunoglobulin protein).

[0110] In addition to the antibody chain gene, the recombinant expression vector disclosed herein carries a regulatory sequence that controls the expression of the antibody chain gene in host cells. The term "regulatory sequence" is intended to include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody chain gene.

[0111] In addition to the antibody chain gene and regulatory sequence, the recombinant expression vector of this disclosure can carry other sequences, such as sequences regulating vector replication in host cells (e.g., origin of replication) and selection marker genes. Selection marker genes help select host cells into which the vector has been introduced. To express the light and heavy chains, the expression vectors encoding the heavy and light chains are transfected into host cells using conventional techniques. Various forms of the term "transfection" are intended to encompass a variety of techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, such as electroporation, lipid transfection, calcium phosphate precipitation, DEAE-glucan transfection, etc.

[0112] The antibodies of this disclosure can be expressed in prokaryotic or eukaryotic host cells. In some embodiments, antibody expression is performed in eukaryotic cells, such as mammalian host cells, that optimally secrete properly folded and immunologically active antibodies. Exemplary mammalian host cells for expressing the recombinant antibodies of this disclosure include Chinese hamster ovary (CHO) cells (including DHFR cells). -CHO cells, described in "Urlaub and Chasin, 1980, Proceedings of the National Academy of Sciences (PNAS) 77:4216-4220", used with DHFR selection markers, such as those described in "Kaufman and Sharp, 1982, Molecular Biology (Mol.biol.) 159:601-621", NSO myeloma cells, COS cells, and SP2 cells. When a recombinant expression vector encoding an antibody gene is introduced into mammalian host cells, antibodies are produced by culturing the host cells for a period of time sufficient to allow expression of the antibody in the host cells or secretion of the antibody into the culture medium in which the host cells are grown. The antibody can be recovered from the culture medium using conventional protein purification methods. Host cells can also be used to produce portions of the complete antibody, such as Fab fragments or scFv molecules. It should be understood that variations of the above procedure are within the scope of this disclosure. For example, it may be desirable to transfect host cells with DNA encoding the light chain or heavy chain (but not both) of the anti-α4β7 antibody disclosed herein.

[0113] Recombinant DNA technology can also be used to remove some or all of the DNA encoding one or both of the light and heavy chains that is not essential for binding human α4β7. Molecules expressed by such truncated DNA molecules are also included in the antibodies disclosed herein.

[0114] To recombinantly express the disclosed anti-α4β7 antibody, host cells can be co-transfected with two of the disclosed expression vectors, the first vector encoding a polypeptide derived from the heavy chain and the second vector encoding a polypeptide derived from the light chain. Both vectors may contain the same selection marker, or they may each contain a separate selection marker. Alternatively, a single vector encoding both the heavy chain and light chain polypeptides may be used.

[0115] Once a polynucleotide encoding one or more parts of an anti-α4β7 antibody is obtained, further alterations or mutations can be introduced into the coding sequence, for example, to generate polynucleotides encoding antibodies with different CDR sequences, antibodies with reduced affinity for the Fc receptor, or antibodies of different subclasses.

[0116] The anti-α4β7 antibody disclosed herein can also be produced by chemical synthesis or by using a cell-free platform.

[0117] 6.5. Purification of anti-α4β7 antibody

[0118] Once the disclosed polypeptide is generated through recombinant expression, it can be purified using any method known in the art for purifying proteins.

[0119] The polypeptide can be purified into a monomer or a dimer, such as an anti-α4β7 antibody containing two polypeptides.

[0120] Once isolated, the anti-α4β7 antibody can be further purified.

[0121] 6.6. Instructions for Use

[0122] 6.6.1. Therapeutic Benefits

[0123] The data presented herein demonstrate that the disclosed anti-human α4β7 antibodies exhibit favorable binding affinity, specificity, and potency for α4β7, as well as favorable binding characteristics for primary immune cells, FcγR binding, and lack of ADCC and ADCP activity on human α4β7+ cells. These anti-human α4β7 antibodies show binding to α4β7 in viral particles from HIV strains grown in different laboratories and from HIV samples from patients, subsequently forming immune complexes. These immune complexes can bind to different FcγRs and are taken up by the human mononuclear cell line THP-1 via phagocytosis. These antibodies also block the interaction of α4β7 with its ligands such as MadCAM-1 and HIV gp120 proteins. Therefore, anti-α4β7 antibodies, binding fragments, and / or pharmaceutical compositions comprising them can be therapeutically used to induce viral suppression of HIV infection or reduce viral load in HIV-infected subjects via Fc-dependent and Fab-dependent mechanisms. In some embodiments, viral suppression of HIV infection involves reducing HIV viral function and / or reducing HIV viral replication.

[0124] The disclosed anti-human α4β7 antibody can be used in methods for treating HIV infection in subjects who require it. In some embodiments, the method involves reducing the viral load in the subject. In some embodiments, the viral load in the subject is reduced to an undetectable level. In some embodiments, the subject is a human subject infected with HIV.

[0125] In some embodiments, the method involves administering an anti-α4β7 antibody that antagonizes α4β7 to provide therapeutic benefit to a human subject infected with HIV. In some embodiments, the method involves administering an anti-α4β7 antibody that binds to HIV viral particles to a human subject infected with HIV. In some embodiments, the method involves administering an anti-α4β7 antibody that binds to α4β7 in HIV viral particles to form an immune complex to a human subject infected with HIV. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV to form an immune complex with HIV viral particles. In some embodiments, these immune complexes are taken up by APCs via phagocytosis. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that blocks the interaction of α4β7 with its ligands such as MadCAM-1 and with HIV gp120. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that blocks the interaction of α4β7 with HIV gp120 to inhibit intercellular HIV transmission. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that blocks CD4 T cell stimulation mediated by MadCAM-1 or HIV gp120. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that inhibits HIV replication in CD4 T cells co-stimulated by MadCAM-1 or HIV gp120. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that induces viral suppression of HIV replication. In some embodiments, the method involves administering an anti-α4β7 antibody to a human subject infected with HIV that induces immune-mediated HIV suppression.

[0126] 6.7. Sequence Description Table

[0127] The correlations of the sequences disclosed in the introduced sequence listing and their brief descriptions are shown in Table 7.

[0128]

[0129]

[0130] 7. Example

[0131] The following examples highlight certain features and characteristics of the exemplary embodiments of the antibodies and binding fragments described herein, and these examples are provided for illustrative purposes and not for limitation.

[0132] Antibody

[0133] The test antibodies used in the examples, including Ab-h1.9d-WT, positive control, and isotype control, are listed in Table 8.

[0134]

[0135] statistics

[0136] Nonlinear regression analysis of the concentration-response curves using GraphPad Prism was used to determine the half-maximum inhibitory concentration (IC50). 50 ) and half-maximum effective concentration (EC50) 50 Values. The significance of the comparisons was determined by the Mann-Whitney two-tailed test. All values ​​are the mean or standard deviation of the results from at least three independent trials, unless otherwise stated.

[0137] 7.1. Example 1: Generation of anti-human α4β7 antibody

[0138] 7.1.1. Hybridoma Screening

[0139] A starting group of mouse anti-human α4β7 antibodies was generated using hybridoma-based technology. Mice were immunized with recombinant cells expressing human α4β7, namely HEK293, CHO-K1, or BaF3, except for adjuvant. The selection of candidate hybridoma-derived antibodies was based on the criteria in Table 9.

[0140]

[0141] A group of functional hybridoma mAbs were identified from this screening, and all candidates showed favorable characteristics. However, none of them exhibited rodent cross-reactivity, which can be explained by the following: 1) human α4 / β7 shares 96% / 97% amino acid sequence homology with cyno α4 / β7, but only 84% / 85% sequence homology with rat and mouse α4 / β7; and 2) all selected functional hybridoma mAbs are highly selective for α4β7 and can bind to conformational epitopes on α4β7 heterodimers.

[0142] 7.1.2. Antibody Characterization

[0143] Small-scale antibody production was carried out in subcloned stable hybridoma cell lines via 200–300 ml roller flask culture and protein A affinity purification. mAb purity was verified by SDS-PAGE and mass spectrometry. The purified antibodies were characterized by binding and functional assays to determine isotype and species cross-reactivity.

[0144] Combined screening

[0145] Antibodies purified for isotype and species cross-reactivity were characterized by FACS at a concentration of 1 μg / ml using BaF3-hα4β7, BaF3-hαEβ7, BaF3-cαEβ7, BaF3, CHOK1-cα4β7, CHOK1-mα4β7, and CHOK1-hα4β1 cell lines. FACS profiles (including exemplary mAbAb-m1 FACS profiles) are summarized in Table 10.

[0146]

[0147] Functional verification

[0148] The purified antibody was characterized by an adhesion assay against MadCAM-1 in HuT78 cells. Ab-m1 demonstrated potential blocking efficacy in the MadCAM-1 assay, thus validating its function. Table 11 summarizes the data from three independent experiments targeting Ab-m1. Figure 1 The data shown is representative.

[0149]

[0150] Functional representation

[0151] Ab-m1 was further functionally characterized using adhesion tests on MadCAM-1 in CHOK1-cα4β7 to examine cyno cross-reactivity. The adhesion test data in CHOK1-cα4β7 are summarized in Table 11 above. Figure 2 The data shown is representative.

[0152] To determine the affinity of Ab-m1 for binding to human α4β7, FACS-based titrations were performed in BaF3-hα4β7. The EC50 was determined and is summarized in Table 12.

[0153]

[0154] Epitope classification was performed by competitive FACS using a comparative antibody conjugated to the Alexa488 fluorophore in the presence of 50-fold excess of the unlabeled Abs shown in Table 13. Based on the percentage of binding inhibition of the unlabeled Abs against the Alexa488 labeled Abs, Ab-m1 was characterized as belonging to the vedolizumab (Ab-Vedo)-like group (Table 13).

[0155]

[0156] Candidate Feature Analysis

[0157] The affinity of mAb for binding to human α4β7 was demonstrated in primary human CD4+ memory T cells. Ab-m1 was also able to highly block the binding of human MadCAM-1 to primary human CD4+ memory T cells (IC50 = 63.7 pM, maximum inhibition 100%). Figure 3 ).

[0158] 7.1.3. VH / VL sequencing, chimeric antibody generation and characterization

[0159] Hybridoma clones were recovered and amplified in complete hybridoma medium (DMEM with 10% FBS). Cells were harvested by centrifugation at 1000 rpm for 5 minutes at room temperature and washed twice with PBS (pH 7.4). The cell pellet (approximately 1 x 10⁻⁶ cells / mL) was separated from the cell pellet with Trizol. 7 RNA was extracted from cells.

[0160] Antibody VH and VL fragments were amplified from total RNA of hybridomas using mouse Ig primers (Novagen, 69831-3) via RT-PCR. Appropriately sized positive PCR products were inserted into a T vector for sequencing and identification of the VH and VL regions (Table 14). Full-length antibody sequences were constructed using combinations of the VH / VL sequences and theoretically defined constant region sequences.

[0161] After designing primers, VL / VH was amplified independently and cloned into an expression vector. Chimeric antibody constructs were then prepared via homologous recombination. The amino acid sequences of CDR in VH and VL are shown in Table 14.

[0162]

[0163] Chimeric antibodies were generated through transient transfection into HEK293 cells. Following expression, the protein was purified. SEC-HPLC confirmed the high percentage of monomeric chimeric antibodies.

[0164] Ab-c1 is a chimeric antibody possessing the variable region of Ab-ml and the constant region of human IgG1 / k. The affinity of Ab-c1 for binding to human primary CD4+CD45RO+ T cells was determined by FACS, with an EC50 value of 3.9 pM for binding from a representative human whole blood sample. Figure 4 (and Table 15). The ability of Ab-c1 to block the binding of α4β7 integrin to MadCAM-1 was also evaluated in HuT78 cells and CHOK1-cα4β7 cells (Table 15).

[0165]

[0166] The purified chimeric antibody Ab-cl was further characterized by FACS at a concentration (1 μg / ml) using BaF3-hα4β7, BaF3-hαEβ7, BaF3-cαEβ7, BaF3, CHOK1-cα4β7, and CHOK1-ha4β1 cell lines to confirm its binding specificity and cynomolgus monkey cross-reactivity. The FACS characteristics of the chimeras are summarized in Table 16.

[0167]

[0168] HuT78 cells were used to investigate whether chimeric Ab-c1 could block MadCAM-1-mediated adhesion to hα4β7 integrin. As shown in Table 17, Ab-c1 demonstrated the ability to inhibit HuT78 cell adhesion to MadCAM-1.

[0169] CHOK1-cα4β7 was used to investigate whether chimeric antibodies could inhibit MadCAM-1-mediated adhesion to cα4β7. As shown in Table 17, Ab-c1 demonstrated the ability to inhibit the adhesion of CHOK1-cα4β7 cells to MadCAM-1.

[0170]

[0171] 7.1.4. Humanization

[0172] The antibody Ab-m1 was selected based on its binding and potency to both HuT78 cells and human primary CD4+ T memory cells, cyno cross-reactivity, CDR sequence diversity, binding selectivity, sequence bias (i.e., glycosylation), and epitope set. Specific characteristics are shown in Table 18.

[0173]

[0174] Assemble the VH and VL fragments according to Table 19, and incorporate human IgG1 and κ constant regions to design humanized antibodies.

[0175]

[0176] These humanized anti-α4β7 mAbs with good expression were generated, and SEC showed >95% monomer content. Identity was confirmed by MS, and stability of the humanized anti-α4β7 was determined by DSC. The ability of four humanized Ab-h1s to block MAdCAM-1-mediated HuT78 cell adhesion was evaluated, and they all showed strong potency with IC50 values ​​in the single-digit or low double-digit pM range (Table 20).

[0177]

[0178] 7.1.5. Predisposition Engineering of Ab-h1.9

[0179] Antibody Ab-h1.9 was selected to generate variant VH and VL chains with reduced chemotaxis in deamidation, isomerization, oxidation, glycosylation, hydrolysis, and cleavage.

[0180] The sequence of Ab-h1.9VH is:

[0181]

[0182] And the sequence of Ab-h1.9VL is:

[0183]

[0184] The selected predisposing mutation sites are underlined, while CDRs are bolded. Predispositions are present in VH-CDR2, VH-CDR3, and VL-CDR1.

[0185] Two rounds of non-biased anti-α4β7 clone selection were performed using biotinylated human α4β7 extracellular domain protein. Colonies from each library were sequenced, and those colonies showing additional bias in any CDR were removed. Clones binding to the yeast surface α4β7 antigen were screened from each library by FACS compared to the parental Ab-h1.9.

[0186] Table 21 shows the engineered clones identified as having a tendency to bind similarly to their parents. Figure 5 These biased engineered clones and their variable regions were converted into IgG forms.

[0187]

[0188] The binding of propensity-modified mAbs Ab-h1.9a to Ab-h1.9e to HuT78 cells expressing α4β7 was tested using FACS. These antibodies retained their binding activity, with EC50 values ​​ranging from 253 pM to 702 pM. This retention of α4β7 binding is surprising, considering that most of VH-CDR3 (e.g., one-third of the amino acid residues in the CDR) is mutated in the propensity-modified mAbs. Ab-h1.9d showed the strongest binding affinity (253 pM) and exhibited good drug-like properties.

[0189] The protein production characteristics of antibody Ab-h1.9(a)-(e) in the form of IgG1 Fc LALA were also tested, and Ab-h1.9d showed superior properties.

[0190] 7.1.6. Antibodies

[0191] Table 22 illustrates exemplary conversions of Ab-h1.9d-derived IgG1 antibodies. Ab-h1.9d-HuIgG1 is a human IgG1 / κ antibody with an HC of SEQ ID NO: 90 characterized by the typical human heavy chain constant region and an LC of SEQ ID NO: 100 characterized by the typical human κ light chain constant region. Ab-h1.9d-HuIgG1 may also have an HC with a C-terminal lysine truncated in SEQ ID NO: 91. Ab-h1.9d-WT is an IgG1 / κ antibody with an HC of SEQ ID NO: 92 characterized by variants CH3-substituted for D356E and L358M and an LC of SEQ ID NO: 100. Ab-h1.9d-WT may also have an HC with a C-terminal lysine truncated in SEQ ID NO: 93. Ab-h1.9d-LALA is an IgG1 / κ antibody with HC of SEQ ID NO: 94, characterized by variant CH2 replacing L234A and L235A and variant CH3 replacing D356E and L358M, and LC of SEQ ID NO: 100. Ab-h1.9d-LALA may also have HC with a C-terminal lysine truncated in SEQ ID NO: 95. Ab-h1.9d-QL is an IgG1 / κ antibody with HC of SEQ ID NO: 96, characterized by variant CH2 replacing T250Q and variant CH3 replacing D356E, L358M, and M428L, and LC of SEQ ID NO: 100. Ab-h1.9d-QL may also have HC with a C-terminal lysine truncated in SEQ ID NO: 97. Ab-h1.9d-LALA / QL is an IgG1 / κ antibody with HC of SEQ ID NO: 98, characterized by variant CH2 replacing T250Q and variant CH3 replacing L234A, L235A, D356E, L358M, and M428L, and LC of SEQ ID NO: 100. Ab-h1.9d-LALA / QL may also have HC with a C-terminal lysine truncated as in SEQ ID NO: 99.

[0192]

[0193]

[0194]

[0195] After its production, Ab-h1.9d-WT exhibited excellent properties of an anti-human α4β7 antibody, demonstrating high specificity (low binding to αEβ7) and the desired PK / PD (low ADA titer and high plasma exposure).

[0196] 7.2. Example 2: Expression of α4β7 in CD4+ and CD8+ T cell subsets from healthy donors or HIV+ individuals

[0197] 7.2.1. Materials and Methods

[0198] During acute HIV infection, CD4+ T cells expressing α4β7 are preferentially infected and thus depleted (Sivro et al., *Science Translational Medicine*, 2018). To investigate whether peripheral α4β7-expressing cells recover over time in HIV-+ individuals receiving cART, the percentage and expression level of α4β7 on CD4+ and CD8+ T cell subsets from PBMCs of 10 healthy (HIV-) donors and 45 HIV-+ individuals receiving cART (age: 26–66 years, median 42 years; duration of HIV infection: 1–36 years, median 12 years) were compared by flow cytometry using a mixture of antibodies against CD3, CD4, CD8, CD28, CD45RO, CCR7, and α4β7. The percentage (%) and expression level (MESF) of α4β7 in the CD4+ and CD8+ T cell populations were analyzed. The CD4+ and CD8+ T cell subsets are defined as: CD28+CD45RO-naïve cells, CD28-CD45RO-terminal effector cells, CD28-CD45RO+ effector memory cells, CD28+CD45RO+CCR7+ central memory cells, and CD28+CD45RO+CCR7-transient memory cells.

[0199] 7.2.2. Results

[0200] For HIV- and HIV+ individuals receiving cART, the percentage of naive CD4+ or CD8+ T cells expressing α4β7 was higher than that of memory T cell subsets, while the α4β7 expression levels (measured by MESF) in central memory, transient memory, and effector memory cells were higher than those in naive cells. Figures 6A to 6F Peripheral CD4+ and CD8+ T cells expressed similar levels of α4β7 in both HIV- and HIV+ individuals (MESF measurement). This analysis indicates that while α4β7 expression on peripheral CD4+ or CD8+ T cells in HIV+ individuals receiving cART is highly variable, it is not different from that in uninfected individuals. These results support the possibility that α4β7 expression in peripheral CD4+ T cells of HIV+ individuals could support α4β7 incorporation into germinating HIV viral particles.

[0201] 7.3. Example 3: Capturing HIV virus particles using Ab-h1.9d-WT

[0202] 7.3.1. Materials and Methods

[0203] To confirm the presence of α4β7 in the HIV viral particle envelope and to test whether Ab-h1.9d-WT could bind to α4β7 incorporated into the HIV viral particle envelope to form an immune complex, Ab-h1.9d-WT was first tested in a viral particle capture assay (bead form) using laboratory-grown HIV-1 strains or samples from viremic HIV+ individuals, following a published method (Guzzo et al., *Science Immunology*, 2017). For laboratory-grown HIV-1 strains, in the presence of retinoic acid (RA), a group of six strains (BCF06, CMU08, NL4-3, RU507, YBF30, and IIIB) representing different groups, genetic subtypes, and co-receptor uses (Table 23) were generated in activated primary human PBMCs [e.g., activated with OKT3 antibody or phytohemagglutinin (PHA)] to induce α4β expression in cells. Protein G-conjugated immunomagnetic beads (Dynabeads, Thermo Fisher) were fitted with appropriate antibodies and then incubated with a viral stock of each HIV strain (approximately 2 ng of p24 gag / reaction). After incubation, the fitted beads were washed to remove unbound viral particles, and then treated with a Triton X-100 to lyse the captured viral particles for p24 gag quantification. For samples from HIV patients, the viral titer (copy / mL) was determined using the COBAS Taqman version 2.0 assay. Protein G-conjugated immunomagnetic beads fitted with 10 μg of appropriate antibody were incubated with 400 μL of patient serum for 2 hours. The beads were then washed to remove unbound viral particles, and RNA from the bound viral particles was extracted using a Qiagen Viral RNA Extraction Kit according to the manufacturer's instructions. The copy number of viral particles captured from patient samples was then quantified by digital droplet PCR using primers and probes targeting the conserved region of the LTR-gag of HIV subtype B.

[0204] To determine the EC of antibodies used to capture HIV viral particles 50The Ab-h1.9d-WT value was tested in a viral particle capture assay converted to a 96-well plate format. Serially diluted antibodies were added to pre-washed Pierce™ Protein G coated plates (Thermo Fisher Scientific). After incubation, the plates were washed to remove unbound antibodies. Viral stock solutions of each HIV strain (approximately 2 ng of p24 gag) were added to each well and incubated. The plates were washed to remove unbound viral particles, and then treated with Triton X-100 to lyse the captured viral particles for p24 gag quantification. HIV p24 gag was detected using a high-sensitivity AlphaLISA p24 gag detection kit (PerkinElmer).

[0205] 7.3.2. Results

[0206] Ab-h1.9d-WT was able to capture viral particles from all six laboratory-grown HIV strains tested, regardless of whether they were clinically or laboratory-adapted strains, as indicated by the viral p24 gag protein in the captured viral particles. Figures 7A to 7F The amount of p24 gag protein from the captured viral particles indicates a dose response to the antibody concentrations (5 and 15 nM) used in the experiment. Ab-h1.9d-WT was also able to capture viral particles from HIV-1 patient samples (viral input shown in...). Figure 7G-1 (in the context of the text, such as the higher number of HIV RNA copies in samples reacted with Ab-h1.9d-WT compared to the negative control antibody, as indicated by the presence of such copies). Figure 7G-2 ).

[0207] Next, Ab-h1.9d-WT was tested in a virus particle capture assay using a modified 96-well plate to determine its efficacy in capturing HIV virus particles. 50 Value. EC values ​​of all tested viruses. 50 The values ​​were similar, ranging from 0.12 nM (0.019 μg / mL) to 0.25 nM (0.038 μg / mL) (Table 23). When tested against the same group of viruses, Ab-Vedo was less effective than Ab-h1.9d-WT in capturing HIV viral particles, with EC50 values ​​lower for each individual virus. 50 EC value compared to Ab-h1.9d-WT 50 The value is approximately 2 to 3 times higher (Table 23). HIV IIIB strains can be transmitted via Ab-h1.9d-WT ( Figure 7F ) and Ab-Vedo (data not shown) use bead-based tests to capture, but their EC 50 The value cannot be determined by plate tests because the viral reservoir has a low titer.

[0208]

[0209] EC 50 = Half maximum effective concentration; IC 50 = Half-maximum inhibitory concentration; ND = Undetermined

[0210] a. The IIIB strain can be captured by Ab-h1.9d-WT and Ab-Vedo in the bead assay, but its EC50... 50 The value cannot be determined by plate test because the viral reservoir has a low titer.

[0211] In summary, these data confirm the presence of α4β7 in viral particles from all laboratory-grown HIV strains and HIV-1 patient samples tested, and demonstrate that Ab-h1.9d-WT is more effective than Ab-Vedo in binding to α4β7 on HIV viral particles to form immune complexes, the first of a series of steps required to induce the proposed “vaccination effect” against persistent HIV virus control.

[0212] Ab-h1.9d-WT is a potent anti-α4β7 antibody that can bind to α4β7 on the viral particle envelope of all tested HIV strains and HIV-1 patient samples.

[0213] 7.4. Example 4: Binding of immune complexes of Ab-h1.9d-WT and HIV viral particles to FcγR

[0214] 7.4.1. Materials and Methods

[0215] To test whether the immune complex formed from Ab-h1.9d-WT and HIV viral particles could bind to FcγR in vitro, an appropriate antibody was first mixed with HIV NL4-3 virus (prepared in activated human PBMCs in the presence of RA to induce α4β7 expression) to form an immune complex. This complex was then incubated with His-tagged FcγR immobilized on a nickel-coated plate [for FcγRI and FcγRIIIa (V158), which have relatively higher affinity for Ab-h1.9d-WT, as shown in Table 32] or biotinylated FcγR immobilized on a neutral avidin-coated plate [for FcγRIIa (H131 or R131) and FcγRIIIa (F158), which have relatively lower affinity for Ab-h1.9d-WT, as shown in Table 32] to increase the sensitivity of the detection. After incubation, the plate was washed to remove unbound FcγR immune complexes, and then treated with lysis buffer to lyse the captured immune complexes to release viral proteins for p24 gag quantification.

[0216] 7.4.2. Results

[0217] The immune complex formed by HIV viral particles and Ab-h1.9d-WT with WT Fc domains can bind to different FcγRs, as shown by the presence of HIVp24 capsid protein in protein complexes that bind FcγRs. Figures 8A to 8E HIV virus particles themselves do not bind to FcγR (data not shown), nor do they bind to the immune complex formed by HIV virus particles and Ab-h1.9d-LALA. Ab-h1.9d-LALA is an antibody identical to Ab-h1.9d-WT except that it has an engineered LALA mutation in its Fc domain to significantly reduce its binding to FcγR. Figures 8A to 8E Furthermore, the immune complexes formed by HIV viral particles and Ab-Vedo exhibit minimal binding to FcγR. Figures 8A to 8E This is consistent with the fact that Ab-Vedo's binding affinity for different FcγRs is significantly lower than that of Ab-h1.9d-WT, which is due to engineered mutations in the Fc domain of Ab-Vedo. Because Ab-h1.9d-WT has lower binding affinity for human FcγRIIa (H131 or R131) and FcγRIIIa (F158, also known as F176) than for FcγRI and FcγRIIIa (V158, also known as V176)... Figure 19A Biotinylated FcγRIIa (H131 or R131) and FcγRIIIa (F158) were immobilized on a neutral avidin-coated plate to enhance the capture of these FcγRs of the immune complex of Ab-h1.9d-WT, instead of using the corresponding His-tagged FcγRs immobilized on a nickel plate.

[0218] The immune complex formed by Ab-h1.9d-WT and HIV viral particles can bind to different FcγRs, including FcγRIIa (responsible for ADCP), a step that allows the complex to be taken up by APCs to induce the proposed “vaccination action” for HIV control.

[0219] 7.5. Example 5: Fc-dependent uptake of α4β7-coated beads mediated by Ab-h1.9d-WT in THP-1 cells

[0220] 7.5.1. Materials and Methods

[0221] Cell culture

[0222] THP-1 cells were cultured at 37°C and 5% CO2 in RPMI medium (Gibco) supplemented with 10% FBS (Sigma). Cells were passaged every 2 to 3 days at a density of 500,000 to 1,000,000 cells / ml.

[0223] Bead preparation

[0224] Recombinant human α4β7 protein (R&D systems) was dialyzed overnight at 4°C in 1x PBS using a 3.5 kDa MWCO dialysis unit (Thermo Fisher Scientific). The resulting α4β7 was then biotinylated for 2 hours at 4°C with a 100-molar excess of NHS-biotin (Thermo Fisher Scientific). Excess biotin was removed by overnight dialyzing at 4°C. Neutral avidin-labeled fluorescent beads (Thermo Fisher Scientific) were incubated with biotinylated α4β7 at 4°C for 1 to 24 hours for α4β7-coated beads. Unless otherwise specified, the bead-protein conjugation reaction occurred at a ratio of 2 mg α4β7 protein per 1 ml of raw beads. The protein-conjugated beads were washed twice with 1x PBS containing 1% BSA (Sigma) and then diluted 100-fold before use. Successful binding of the protein to the beads was confirmed in a phagocytosis assay comparing anti-α4β7 with isotype control conditions.

[0225] Phagocytosis test

[0226] Phagocytosis assays using protein-coated beads and THP-1 cells were modified from a previously described study (Ackerman et al., 2011). The assays were performed in 96-well plates. Immune complexes were formed by combining 10 μL of prepared α4β7-coated beads with 10 μL of the indicated antibody (10 μg / ml). These were incubated at 37°C and 5% CO2 for 1–2 hours. THP-1 cells (100,000 / well) were then incubated with the immune complexes in a final volume of 200 μL for the specified duration. After incubation, cells were stained with a fixable live / dead staining agent (Thermo Fisher Scientific), followed by washing and fixation with FACS buffer. Data on the resulting cells were collected using a BD LSR Fortessa X20. Fluorescence of the beads and live / dead staining was detected using PE-CF594 and BV510 settings, respectively. Data were then analyzed using FlowJo software. The phagocytosis score is calculated as follows: Phagocytosis score = (MFI × percentage of bead-positive cells) / 1000. Normalization: Data from three independent experiments are normalized and plotted on a single graph. To normalize, one replicate under the "bead-only" condition is set to 1 by dividing this value by the same value (per experiment). All other values ​​are divided by this normalized value to show the normalized phagocytosis score, representing the fold change under the "bead-only" condition.

[0227] Imaging flow cytometry

[0228] Internalization of the fluorescent beads was confirmed using imaging flow cytometry. Fixed cells were analyzed on an ImagestreamX Mark II imaging flow cytometer (Luminex Corp.) at 40x magnification, medium sensitivity, and medium speed settings. The fluorescent beads were imaged using 488 nM (5 mW) / 560–595 nM (excitation / emission). Live / dead cell staining was imaged using 405 nM (5 mW) / 430–480 nM (excitation / emission). Bright-field images were acquired in channel 2 (camera 1). Data were analyzed using IDEAS analysis software v6.1 (Luminex Corp.). A standard gating strategy was used to identify suitable cell populations. In short, high (>40) gradient RMS (root mean square) was used to identify focused cells based on bright-field image sharpness. Individual cells were identified by the high aspect ratio and low target area of ​​the bright-field images. Cell target regions were identified in the bright-field images, and an "intracellular mask" was defined by eroding 4 pixels from the cell boundary. Cells exhibiting positive fluorescence signals in an intracellular mask were identified as having genuine internalization events. The number of internalized beads in cells exhibiting genuine internalization events was counted using a spot counting feature. At least 2000 cells exhibiting genuine internalization events were analyzed for each sample.

[0229] Statistical analysis

[0230] Plot the data using GraphPad Prism. Determine significance using one-way ANOVA combined with the graph base multiple comparison test. ****p<0.0001, ***p=0.0001-0.001, **p=0.001-0.01, *p=0.01-0.05.

[0231] 7.5.2. Results

[0232] The uptake of immune complexes by antigen-presenting cells is crucial for initiating downstream cellular and humoral immunity. THP-1 cells have been reported to phagocytose antibody-fluorescent bead immune complexes in an Fc / FcγR-dependent manner (Ackerman et al., 2011). Therefore, THP-1 cells were used to investigate whether Ab-h1.9d-WT mediates the phagocytosis of α4β7-coated fluorescent beads. Cells treated with α4β7-beads / Ab-h1.9d-WT antibody immune complexes for 3 hours showed significant uptake of fluorescent beads associated with Ab-h1.9d-LALA and Ab-Vedo (characterized by LALA) by flow cytometry. Figures 9A to 9B It is known that LALA mutations significantly reduce the binding of IgG Fc to FcγR. These data indicate that Ab-h1.9d-WT mediates a robust Fc / FcγR-dependent phagocytosis of immune complexes containing α4β7-coated fluorescent beads.

[0233] Imaging flow cytometry using Amnis Imagestream was used to confirm the internalization of the Ab-h1.9d-WT / α4β7-bead immune complex in THP-1 cells. As expected, following treatment with the Ab-h1.9d-WT immune complex, the fluorescent beads were localized within THP-1 cells. Figure 9C ).

[0234] 7.6. Example 6: The uptake of α4β7+GFP+VLP / Ab immune complexes in Ab-h1.9d-WT-induced THP-1 cells is α4β7 and Fc dependent. 7.6.1. Materials and Methods

[0235] Antibodies were used to bind to GFP+ virus-like particles (VLPs) expressing α4β7 via ELISA.

[0236] α4β7+GFP+VLPs were generated from HEK293 cells transfected sequentially with α4β7 cDNA and HIV gag-GFP DNA constructs, and the VLPs were subsequently purified from the cell culture supernatant. ELISA was performed to confirm α4β7 expression on the GFP+VLP surface and the binding specificity of various assay antibodies. Briefly, each well of a high-binding flat-bottom 96-well plate was coated with 50 μL of α4β7+GFP+VLP at a concentration of 7.5 x 10⁷ particles / mL in PBS and incubated overnight at 4°C. The wells were washed with PBS + 1% FBS and blocked with 100 μL of superblocking solution at room temperature (RT) for 30 min. After three washes, each well was incubated with 50 μL of a 4-fold serially diluted primary antibody in PBS + 1% FBS for 1 h at room temperature, followed by washing and incubation with 50 μL of HRP-conjugated donkey anti-human IgG-Fcγ-specific secondary antibody in PBS + 1% FBS for 1 h at room temperature. After the final wash, TMB substrate was added to each well for color development, and the reaction was terminated by adding 2N H2SO4. The optical density (OD) of each well was measured at 450 nM using a plate reader.

[0237] Internalization of the α4β7+GFP+VLP / anti-α4b7 immune complex in THP-1 cells

[0238] For the α4β7+GFP+VLP uptake assay, 5 x 10⁻⁶ ppm of antibody were used, with or without a final concentration of 1 μg / mL. 4 THP-1 cells and α4β7+GFP+VLPs were mixed in 100 μL of RPMI (containing 10% FBS) in a flat-bottom 96-well plate at a cell-to-particle ratio of 1:100. The plate was incubated at 37°C in a CO2 incubator for 16 hours. The cells were then resuspended and transferred to a V-bottom 96-well plate, and washed once with 200 μL of PBS (containing 2% FBS) by centrifugation. The cell pellet was resuspended in 200 μL of PBS (containing 0.5% paraformaldehyde), and the percentage of GFP+ cells was determined by flow cytometry.

[0239] To inhibit VLP uptake, THP-1 cells (0.5 x 10⁶ / mL) were pretreated for 2 hours in a CO₂ incubator at 37°C with or without LatA at a final concentration of 240 nM or with 0.1% DMSO (control), and then incubated with α4β7+GFP+VLP with or without antibody, as described above.

[0240] 7.6.2. Results

[0241] Ab-h1.9d-WT-induced uptake of the α4β7+GFP+VLP / Ab immune complex in THP-1 cells is α4β7 and Fc dependent.

[0242] Recombinant virus-like particles (VLPs) generated from mammalian cells exhibited a dynamic size ranging from 0.1 to 0.2 micrometers. Therefore, they were more similar in size to viral particles compared to fluorescently labeled beads used in previous experiments and served as a tool to mimic the internalization / uptake of α4β7+ viral particle / antibody immune complexes by THP-1 cells. The ability of purified α4β7-expressing GFP+ VLPs to bind to anti-α4β7 Ab was evaluated by ELISA. Figure 10 As shown, Ab-h1.9d-WT, Ab-h1.9d-LALA, and Ab-Vedo bound to α4β7+GFP+VLP with similar EC50 values ​​(0.050 nM, 0.048 nM, and 0.058 nM, respectively), while the isotype control Ab (anti-CMV IgG) did not bind to α4β7+GFP+VLP at all. These data indicate that various anti-α4β7 Abs can bind to α4β7+GFP+VLP with good binding affinity and specificity.

[0243] Next, the uptake of α4β7+GFP+VLP by THP-1 cells was evaluated in the presence of various anti-α4β7 Abs with and without functional Fc. Figure 11A As shown, compared to 1.2% of GFP+ cells treated with the isotype Ab control, Ab-h1.9d-WT treatment induced more than 60% of GFP+ THP-1 cells, representing a 50-fold increase in GFP+ cell induction. This indicates that the uptake of α4β7+GFP+VLP by THP-1 cells is Ab-h1.9d-WT specific and dependent on α4β7 expression. However, Ab-h1.9d-LALA or Ab-Vedo (LALA) showed only minimal VLP uptake in THP-1 cells, suggesting that the anti-α4β7 Ab-induced α4β7+GFP+VLP uptake in these cells requires not only the α4β7-binding Fab domain but also the functional Fc domain of the antibody to enable Fc / FcγR-mediated immune complex internalization.

[0244] To confirm that Ab-h1.9d-WT-mediated α4β7+GFP+VLP uptake is indeed due to internalization, and not merely binding to cell surface FcγR, the known internalization inhibitor Lat-A (Lat-A) was used to pretreat THP-1 cells before incubation with the Ab / VLP immune complex. Figure 11BAs shown, compared with untreated cells, Lat A-treated cells had 40% fewer GFP+ cells. This suggests that at least 40% of the total GFP signal observed in the untreated (simulated) or DMSO-treated controls is generated by Ab-h1.9d-WT-dependent VLP internalization in THP-1 cells.

[0245] 7.7. Example 7: Ab-h1.9d-WT showed no neutralizing activity against HIV.

[0246] 7.7.1. Materials and Methods

[0247] Some antibodies (Abs) capable of binding to HIV viral particles, such as broad-spectrum HIV neutralizing antibodies, can block viral infection. To test whether the binding of Ab-h1.9d-WT to α4β7 on HIV viral particles could block HIV infection in host cells, it was evaluated in a virus neutralization assay using the TZM-b1 indicator cell line (Arrildt et al., Journal of Virology, 2015).

[0248] HIV neutralization test

[0249] HIV virus (prepared in the presence of PHA and RA) equivalent to approximately 150,000 RLU (previously determined by viral titration on TZM-bl cells) was pre-incubated with serially diluted antibodies. TZM-bl cells containing DEAE-glucan were added to a mixture containing the pre-incubated HIV and antibodies, and then incubated at 37°C for 48 hours. Cells were treated with Bright-Glo (Promega) and luciferase signal was measured.

[0250] 7.7.2. Results

[0251] When tested against one group of HIV strains shown in Table 23, Ab-h1.9d-WT showed no neutralizing activity at concentrations up to 50 μg / mL, while the broad-spectrum neutralizing antibody targeting the CD4+ binding site had a neutralizing IC50 of approximately 0.1 μg / mL against all tested group M HIV strains (i.e., CMU08, NL4-3, and RU570). 50 Value (data not shown).

[0252] Although Ab-h1.9d-WT binds to HIV viral particles, it does not neutralize HIV infection, consistent with the view that α4β7 is not a viral receptor on host cells. This observation supports the hypothesis that targeting α4β7, rather than viral-encoded glycoproteins, can circumvent viral resistance mechanisms.

[0253] 7.8. Example 8: Inhibition of the interaction between α4β7 and HIV gp120 by different antibodies

[0254] 7.8.1. Materials and Methods

[0255] It has been reported that the interaction between α4β7 and HIV gp120 activates LFA-1, potentially promoting intercellular HIV transmission (Arthos et al., *Nature Immunology*, 2008). To test whether Ab-h1.9d-WT could disrupt this interaction, an α4β7 / gp120 binding assay was established using RPMI 8866 cells expressing α4β7 that bound to an HIV gp120-V2 peptide immobilized on a plate, following a published method (Peachman et al., *PLOS ONE*). High-capacity 96-well plates (Thermo Fisher Scientific) coated with neutral avidin were used with either biotinylated HIV gp120-V2 WT or the gp120-V2 control peptide (Table 24). The sequences of the two biotinylated peptides were identical except for the four amino acids reported to mediate the binding between α4β7 and gp120 in the control peptide, which were mutated.

[0256]

[0257] *Different amino acids between the two polypeptides are shown in bold.

[0258] Before adding the antibody-cell mixture, the peptide-coated plate was washed to remove unbound peptides. To generate the antibody-cell mixture stock solution, RPMI 8866 cells (8 x 10⁻⁶) were added. 6 Cells / mL were resuspended in cold blocking buffer supplemented with MnCl2 to a final concentration of 2 mM to activate the α4β7 conformation. Serially diluted Ab-h1.9d-WT, Ab-Vedo, or allotype negative control antibody were mixed with MnCl2-treated cells and incubated. The antibody-cell mixture (2 x 10⁻⁶ cells / mL) was then incubated. 5 50 μL of cells per well were added to each well of a plate coated with gp120 peptide and incubated. The plate was washed, and viable cells attached to the peptide-coated plate were identified using CellTiter-Glo 2.0 reagent (Promega).

[0259] 7.8.2. Results

[0260] The specificity of this experiment was demonstrated by the binding of RPMI 8866 cells expressing α4β7 to HIV gp120-V2WT peptide immobilized on a plate, rather than to immobilized gp120-V2 control peptide. Figure 12AThe fixed gp120-V2 control peptide contained a mutation at four amino acids reported to mediate the binding of gp120 to α4β7 (Table 24). When tested in this assay, Ab-h1.9d-WT blocked the binding of RPMI 8866 cells to the HIV gp120-V2 WT peptide, IC50... 50 The value was 0.022 ± 0.016 μg / mL. Figure 12B When tested in the same experiment, Ab-Vedo has a higher IC than Ab-h1.9d-WT. 50 The value (0.042±0.023 μg / mL) indicates that it is less effective than Ab-h1.9d-WT in blocking this interaction. Figure 12B In summary, these results indicate that Ab-h1.9d-WT can effectively disrupt the interaction between α4β7 and gpl20, potentially inhibiting intercellular viral spread.

[0261] When tested in this experimental format, Ab-h1.9d-WT blocked the binding of RPMI 8866 cells to the HIV gp120-V2WT peptide, IC50. 50 The value was 0.022 ± 0.016 μg / mL. Figure 12B These results indicate that Ab-h1.9d-WT can effectively disrupt the interaction between α4β7 and gp120, potentially inhibiting intercellular viral spread.

[0262] 7.9. Example 9: Binding of Ab-h1.9d-WT to human and cynomolgus monkey cells expressing α4β7 integrin

[0263] 7.9.1. Materials and Methods

[0264] The binding of Ab-h1.9d-WT was evaluated using an ECL binding assay on HuT78 cells (human T lymphoma cells expressing endogenous α4β7) and by flow cytometry on human and cynomolgus monkey peripheral lymphocytes.

[0265] In addition, the binding EC of Ab-h1.9d-WT was determined. 50 The values ​​were compared between total, naive, and memory CD4+ and CD8+ T cells derived from human and cynomolgus monkey blood.

[0266] ECL cell binding assay

[0267] HuT78 cells expressing endogenous α4β7 were cultured in IMDM medium containing 20% ​​FBS, penicillin (50 units / mL) / streptomycin (50 μg / mL). HuT78 cells were collected, washed once, and cultured at 1.5 x 10⁻⁶ cells / mL. 6Resuspend cells / mL in DPBS. (50 μL containing 7.5 x 10⁻⁶ cells / mL) 4 Add cells to each well of an MSD high-binding plate. Add 6.7% fetal bovine serum (diluted in DPBS) and incubate the plate at 37°C for 1 hour. Remove the supernatant and add 25 μL of Ab-h1.9d-WT antibody or allotype control prepared in an 8-point dilution (1:4) ranging from 1.5 μg / mL to 0.000091 μg / mL (in DPBS buffer containing 5% FBS and 1 mM MnCl2) to each well, then incubate at 37°C for 1 hour. Wash the plate twice with DPBS and add 25 μL of goat anti-human Ab sulfotag diluted 1:500 in 5% FBS / DPBS / 1 mM MnCl2 to each well, then incubate at 37°C for 30 minutes. Wash the cells twice with DPBS and add 150 μL of 2x MSD read buffer T to each well. The board was read using a Sector Imager 6000 reader, and the bonding curves and bonding ECs were generated using GraphPad Prism 7.0 software. 50 value.

[0268] Human-cynomolgus monkey peripheral T cell binding assay

[0269] Thaw frozen human or cynomolgus monkey PBMCs (isolated from blood donors using standard sucrose plate separation methods) in RPMI 1640 / 10% FBS medium, and use FACS buffer (DPBS, w / o Ca) +2 / Mg +2 Wash once with 1% BSA and resuspend in FACS buffer containing 5% goat serum. Add approximately 1-2 x 10⁻⁶ g of the solution. 5Cells (in 100 μL) were added to 96-well U-shaped plates and incubated on ice for 30 minutes. The plates were centrifuged and the supernatant was removed. A mixture of titrated Ab-h1.9d-WT or allotype control (25 μL) and fluorescently labeled antibody (25 μL), prepared by a 1:5 dilution in FACS buffer containing 5% goat serum with a final concentration ranging from 5 to 0.000016 g / mL, was added to each well, and the plates were incubated on ice for 1 hour. Compensation and FMO controls were also prepared. After incubation, the cells were centrifuged and washed twice with FACS buffer. A secondary antibody (PE-conjugated) was diluted 1:2,000 in FACS buffer containing 5% goat serum, and 50 μL was added to each well. The plates were incubated on ice for 1 hour. After incubation, the cells were washed twice with FACS buffer and resuspended in 200 μL of PBS containing 0.5% PFA. Plate readings were performed on FACS (Canto II, BD), and live cells were gated based on forward and side scattering. Flow cytometry data (FCS 3.0 files) were analyzed using FlowJo version 10 software, and binding curves and binding EC were generated using GraphPad Prism 7.0 software. 50 value.

[0270] 7.9.2. Results

[0271] ECL cell binding

[0272] As summarized in Table 25, Ab-h1.gd-WT showed binding EC50 values ​​of 26 pM, 130 pM, and 62 pM to HuT78 cells, human and cynomolgus monkey blood-derived lymphocytes, respectively. 50 value.

[0273]

[0274] *Mean ± standard deviation; N = 3 (people) or N = 5 (cynomolgus monkeys)

[0275] Human-cynomolgus monkey peripheral T cell binding assay

[0276] Ab-h1.9d-WT binding EC50 of total, naïve, and memory CD4+ and CD8+ T cells derived from human and cynomolgus monkey blood. 50 The values ​​are shown in Table 26.

[0277]

[0278] CD4+ initial = CD4+CD45RA+CCR7+ cells, CD4+ memory = CD4+CD45RA- cells

[0279] CD8+ initial = CD8+CD45RA+CCR7+ cell, CD8+ memory = CD8+CD45RA- cell

[0280] a. Human PBMC = 3 donors

[0281] b. Cynomolgus monkey PBMC = 5 donors

[0282] The average binding of EC on all evaluated T cell subsets 50 The values ​​ranged from 10 to 165 pM. Ab-h1.9d-WT was very similar to the binding of human and cynomolgus monkey CD4+ and CD8+ T cells or their subsets, as the mean EC50 values ​​for each corresponding cell type differed by only 2 to 3 times between the two species.

[0283] The binding of Ab-h1.9d-WT to human and cynomolgus monkey CD4+ and CD8+ T subsets was also analyzed to compare the percentage of T cell subsets bound by Ab-h1.9d-WT, such as... Figure 13 As shown. In summary, the percentage of Ab-h1.9d-WT binding cells in each T cell subset is comparable between humans and cynomolgus monkeys. These findings are not surprising, as α4 and β7 from both humans and cynomolgus monkeys are highly homologous (97% amino acid identity, see Table 27).

[0284]

[0285] Furthermore, in vivo studies confirmed the functional cross-reactivity of Ab-h1.9d-WT in cynomolgus monkeys. Repeated administration of Ab-h1.9d-WT to cynomolgus monkeys resulted in an increase in peripheral blood CD4+ T cell counts when the α4β7 receptor was fully occupied. These data demonstrate the target functional pharmacodynamic effects of Ab-h1.9d-WT and support the use of cynomolgus monkeys as a pharmacologically relevant species for the toxicological evaluation of Ab-h1.9d-WT.

[0286] In summary, Ab-h1.9d-WT strongly binds to both human and cynomolgus monkey CD4+ and CD8+ T subgroups, indicating excellent cynomolgus monkey binding cross-reactivity.

[0287] 7.10. Example 10: Integrin binding specificity of Ab-h1.9d-WT

[0288] 7.10.1. Materials and Methods

[0289] Recombinant cells expressing their respective human and cynomolgus monkey heterodimer integrins α4β7, α4β1, and αEβ7 enabled the evaluation of Ab-h1.9d-WT binding specificity.

[0290] The nonspecific binding of Ab-h1.9d-WT to human epithelial HEK293 cells was also evaluated.

[0291] Integrin binding specificity assay

[0292] CHO-K1 or BAF3 cells expressing various human and cynomolgus integrins (α4β7, α4β1, or αEβ7) except for cynomolgus α4β1 were harvested, counted, and incubated in FACS buffer (DPBS, w / o Ca+2 / Mg+2, 1% BSA) at 1.5 x 10⁻⁶ cells / mL. 6 The density of individual cells was prepared. The sample contained 1.5 x 10⁻⁶ cells. 5 100 μL of each cell was added to each well of a 96-well U-shaped plate, and the supernatant was removed by centrifugation. 100 μL each of Ab-h1.9d-WT, experimental control, or allotype control in FACS buffer was added to reconstitute the cell pellet. The contents of the wells were mixed, and the plates were incubated on ice for 1 hour. The cells were washed twice with FACS buffer, and 100 μL of a 1:600 ​​dilution of the secondary antibody (goat anti-hu IgG Fcγ-specific Alexa Fluor 488) in FACS buffer was added to each well and mixed. The plates were incubated on ice for 45 minutes. Subsequently, the cells were washed twice with FACS buffer and resuspended in 200 μL of PBS containing 0.5% PFA. The plates were read on a FACS (Canto-II, BD) instrument, and viable cells were identified based on forward and side scattering. The median fluorescence intensity of the cell-binding antibody was generated using GraphPad Prism 7.0 software.

[0293] For CHO-K1 cells expressing cynomolgus monkey α4β1, an antibody staining mixture containing 25 μL of a 1:25 dilution of CD29-APC and CD49d-BV421 mixture, along with 25 μL of Ab-h1.9d-WT (prepared by serial dilution 1:5 in FACS buffer), an experimental control, or an allotype control, was added to each well of a 96-well U-shaped plate to reconstitute the cynomolgus monkey α4β1 cell pellet. The contents of the wells were mixed, and the plates were incubated on ice for 45 minutes. A staining control was also prepared. Cells were washed twice with FACS buffer, and then 50 μL of a secondary antibody (goat anti-hu IgG Fcγ-specific PE) diluted 1:600 ​​in FACS buffer was added to each well and mixed. The plates were incubated on ice for another 45 minutes. Subsequently, the cells were washed twice with FACS buffer and resuspended in 200 μL of PBS containing 0.5% PFA. Plates were read on an FACS (Canto-II, BD) instrument, and live cells were gated based on both forward and side scattering. CD29+CD49d+ cells were then gated using FlowJo version 10 software to determine the median fluorescence intensity for cell binding assay antibodies. Data were plotted using GraphPad Prism 7.0 software.

[0294] Nonspecific HEK293 cell binding assay

[0295] HEK293G cells were cultured in complete DMEM (DMEM + 10% FBS + 1% sodium pyruvate). Cells were harvested using non-enzymatic dissociation buffer (Gibco, catalog number 13151-014), counted, and cultured at 1.5 x 10⁻⁶ cells / mL. 6 Resuspend cells / mL in FACS buffer (2% BSA / PBS). Disperse 7.5 x 10⁻⁶ cells / mL into each well of a 96-well U-shaped plate. 4 Cells were added to each well with 100 μg / mL of Ab-h1.9d-WT, positive control antibody, or allotype control antibody and incubated on ice for 1 hour. After incubation, cells were washed twice with FACS buffer and then incubated on ice for 30 minutes with 100 μL of goat anti-hu IgG Fc-PE (Jackson, catalog number 109-116-098) diluted 1:100 in FACS buffer. Cells were then washed twice with FACS buffer and resuspended in 200 μL of FACS buffer. Plate readings were performed using FACS (Canto II, BD). Binding data were analyzed using GraphPadPrism 7.0 software.

[0296] 7.10.2. Results

[0297] Integrin binding specificity

[0298] like Figures 14A to 14C As shown, Ab-h1.9d-WT specifically binds to cells expressing human α4β7 but not to cells expressing human α4β1, while anti-α4 mAb and Ab-naa bind to both integrins. Compared to the much stronger binding observed against anti-β7 mAb (investigation-grade itrarib monoclonal antibody), Ab-h1.9d-WT binds minimally to cells expressing human αEβ7. Ab-h1.9d-WT exhibits binding specificity characteristics similar to cynomolgus integrins. These data demonstrate that Ab-h1.9d-WT has binding specificity for both human α4β7 and cynomolgus α4β7.

[0299] Non-specific HEK293 cell binding

[0300] The non-specific binding of Ab-h1.9d-WT to human epithelial HEK293 cells was also evaluated. Figure 15 As shown, Ab-h1.9d-WT did not show any nonspecific binding to HEK293 cells at a high concentration (100 μg / mL), which was comparable to the control antibody, while the positive control mAb showed strong nonspecific binding to these cells.

[0301] 7.11. Example 11: Rabbit and rodent binding cross-reactivity of Ab-h1.9d-WT

[0302] 7.11.1. Materials and Methods

[0303] The binding of Ab-h1.9d-WT to PBMCs isolated from rabbits, rats, and mice was evaluated by flow cytometry.

[0304] Rabbit and rodent cross-reactivity binding test

[0305] Thaw rabbit PBMCs and place them in RPMI 1640 / 10% FBS medium, using FACS buffer (DPBS, w / o Ca). +2 / Mg +2 Wash once with 1% BSA and resuspend in FACS buffer containing 5% goat serum. Add cells (1 x 10⁻⁶ cells / mL) to a solution containing 1% goat serum. 5Cells were aliquoted into 96-well U-shaped plates and incubated on ice for 30 minutes. The plates were centrifuged to remove the supernatant, and 25 μL of titrated Ab-h1.9d-WT or allotype control, along with 25 μL of 1:10 diluted CD4-FITC antibody (all Abs diluted in FACS buffer), were added to each well to reconstitute the cell pellet. The contents of the wells were mixed, and the plates were incubated on ice for 45 minutes. Appropriate staining controls were also prepared. Subsequently, the cells were washed twice with FACS buffer, and 50 μL of a second antibody-PE diluted 1:2000 in FACS buffer containing 5% goat serum was added to the cell pellet. The plates were further incubated on ice for 45 minutes. The cells were washed twice with FACS buffer and resuspended in 200 μL of PBS containing 0.5% PFA. The plates were read on a FACS (Canto II, BD) instrument, and live cells were gated based on forward and side scattering. The percentage of antibody-bound cells was determined using FlowJo version 10 software, and binding curves and binding EC were generated using GraphPad Prism 7.0 software. 50 value.

[0306] Female C57BL / 6N mice and female Lewis rats were obtained from Taconic Laboratories and Charles River Laboratories, respectively. PBMCs were isolated from the blood of the combined mice and rats. Red blood cells were lysed using RBC lysis buffer (eBioscience). Cells were washed once in PBS and resuspended in FACS buffer (DPBS, w / o Ca) containing 5% goat serum. +2 / Mg +2 In 1% BSA. Approximately 2.5 x 10 5100 μL of cells were added to each well of a 96-well U-shaped plate and incubated on ice for 30 minutes. Except for Ab-h1.9d-WT or the allotype control, a 1:50 dilution of an appropriate fluorescent dye-conjugated antibody was added to mouse cells (CD3-APC, α4β7-PE, or IgG2a-FITC control) or rat cells (CD3-APC, α4-FITC, or IgG2a-PE control). The contents of the wells were thoroughly mixed, and the plate was incubated on ice for 1 hour. The final concentrations of the allotype control and Ab-h1.9d-WT were 10 μg / mL and 1 μg / mL, respectively. Subsequently, the cells were washed twice with FACS buffer, and 100 μL of a 1:800 dilution of the secondary antibody-PE or secondary antibody-AF488 was added to each well, and the plate was incubated on ice for 45 minutes. After incubation, cells were washed twice with FACS buffer and resuspended in 200 μL of PBS containing 0.5% PFA. The plates were read on an FACS (Canto II, BD) instrument, and live cells were gated based on forward and side scattering. The percentage of CD3+ cells binding to the test antibody or allotype control was determined using FlowJo version 10 software, and graphs were plotted using GraphPad Prism 7.0 software.

[0307] 7.11.2. Results

[0308] As summarized in Table 28, Ab-h1.9d-WT showed similar binding EC50 to rabbit lymphocytes and CD4+ T cells compared to its human and cynomolgus monkey counterparts. 50 The values ​​were positive, while Ab-h1.9d-WT did not show any measurable binding to rat or mouse PBMCs (lymphocytes and CD4+ T cells).

[0309]

[0310] EC50 values ​​determined using the percentage of α4β7-expressing lymphocytes and CD4+ cells.

[0311] a. Human / Rabbit PBMC = 3 donors

[0312] b. Cynomolgus monkey PBMC = 5 donors

[0313] c. PBMCs from mixed-blood rodents

[0314] 7.12. Example 12: Ab-h1.9d-WT-induced α4β7 internalization

[0315] 7.12.1. Materials and Methods

[0316] The ability of Ab-h1.9d-WT to induce cell surface α4β7 internalization in human primary CD4+ and CD8+ naïve T cells from two PBMC donors was investigated.

[0317] Internalization test

[0318] The internalization of Ab-hi.9d-WT was investigated and quantified using a FACS protocol similar to that used to determine the cellular mechanism of action of itratriol (Lichnog et al., Frontiers in Pharmacology). Peripheral blood mononuclear cells (PBMCs) were isolated from two healthy blood donors (RBCs, donors KP58219 and KP58239) using Ficoll Paque lymphocyte separation medium (GE 17-1440-03) and SepMate density gradient centrifuge tubes (StemCell 85450), resuspended in FBS containing 5% DMSO (Gibco 10438-026), and cryopreserved in liquid nitrogen. The frozen PBMCs were thawed, counted, and centrifuged in RPMI medium + 10% FBS at 1x10⁻¹. 6 Restore 100 μL of cells per well at 1 x 10⁶ cells / mL. 5 Cells were plated. The plated cells were then incubated at 4°C or in a 37°C, 5% CO2 incubator for 30 minutes to allow the plates to acclimatize. Human PBMCs were pre-incubated at 4°C for 1 hour with 100 μL of 1.25 μg / mL unlabeled Ab-h1.9d-WT antibody (final concentration 0.625 μg / mL). Cells were centrifuged, washed, and resuspended in 200 μL RPMI + 10% FBS, and incubated at 4°C or 37°C, 5% CO2 for 18 hours. After incubation, cells were washed twice with FACS buffer (PBS + 1% FBS) and then stained for 30 minutes with CD4+ (Biolegend 317410), CD8+ (Biolegend 344710), and CD45RA (Biolegend 304130) with or without AF647-labeled non-competitive anti-β7 antibody. Cell fluorescence was obtained using flow cytometry (LSR-Fortessa). Data were analyzed using FlowJo version 10 software and the percentage of internalization was calculated as 100x [total cell surface α4β7 expression before internalization (MFI at 4°C) - remaining cell surface α4β7 expression after internalization (MFI at 37°C) / total cell surface α4β7 expression before internalization (MFI at 4°C)].

[0319] 7.12.2. Results

[0320] like Figure 16AAs shown, when Ab-h1.9d-WT was evaluated 18 hours after binding to human PBMCs at 4°C for minimal internalization, 73% of CD4+ naive T cells (CD4+CD45RA) from donor 1 were evaluated. + ) and 49% of CD8+ naive T cells (CD8+CD45RA) + β7 positivity was maintained. However, after incubating Ab-h1.9d-WT at 37°C under the same protocol to promote internalization, only 17% of CD4+ naive T cells and 7% of CD8+ naive T cells were found to be β7 positive. These data suggest that significant internalization of surface α4β7 bound to Ab-h1.9d-WT occurs at 37°C. Similar results were observed using PBMCs from donor 2. Figure 16B The quantification of α4β7 internalization at 37℃ (compared to the expression observed after treatment at 4℃, surface α4β7 expression was reduced), Ab-h1.9d-WT was able to quantify α4β7 internalization. + Approximately 80% of α4β7 internalization is induced on naïve CD4+ and CD8+ T cells.

[0321] Compared to Ab-Vedo, Ab-h1.9d-WT is more effective in inducing α4β7 internalization.

[0322] 7.13. Example 13: Blocking of MAdCAM-1 ligand by Ab-h1.9d-WT

[0323] 7.13.1. Materials and Methods

[0324] MAdCAM-1 ligand blocking assay

[0325] For FACS-based experiments, harvest HuT78 cells or human PBMCs, wash once with DPBS, and adjust to a concentration of 1.5 x 10⁻⁶. 6 Cells were collected at a density of [number] cells / mL and resuspended in FACS buffer (DPBS, w / o Ca2+). +2 / Mg +2 In 1% BSA / 1mM MnCl2, cells were inoculated at a concentration of 1 x 10⁻⁶ mM. 5(100 μL) / well was dispensed into 96-well U-shaped plates and centrifuged to remove supernatant. 50 μL of titrated Ab-h1.9d-WT or allotype control was added to each well along with 50 μL of a mixture containing 0.3 μg / mL MAdCAM-1-mFc, 2 mM MnCl2, and Alexa488-conjugated detection Ab (30 μg / mL) diluted 1:50 in FACS buffer. The plate was incubated on ice for one hour, followed by centrifugation. The plate was gently washed once with 200 μL of FACS buffer, and cells were reconstituted in the same buffer. The plates were read using FACS (Canto II), and viable cells were identified by forward and side scatter gating. Flow cytometry data (FCS 3.0 file) were analyzed using FlowJo version 10 software, and binding curves and inhibition IC50 were generated using GraphPad Prism 7.0 software. 50 value.

[0326] For plate-based experiments, use coating buffer (PBS w / o Ca). +2 / Mg +2 96-well flat-bottom plates (Greiner, catalog number 655077) were coated overnight at 4°C with 100 μL of 20 μg / mL MAdCAM-1hFc or a homologous control (final concentration 2 μg / well) containing 0.1% BSA. The next day, the plates were washed with 200 μL of wash buffer (PBS w / Ca). +2 / Mg +2 Wash the plate twice with 0.1% BSA, then use blocking buffer (PBS w / Ca). +2 / Mg +2 Blocked at 37°C for 1 hour with 1% BSA. During the blocking incubation, dilutions of Ab-h1.9d-WT and isotype control were prepared, and HuT78 cells were harvested. A 2-fold initial concentration of 5 μg / mL was prepared, followed by a series of 7-point dilutions at a ratio of 1:4.5 (final concentration range 2.5 to 0.0003 μg / mL) in duplicate or triplicate. Cells were counted, washed, and dilute with 2 x 10⁻⁶ BSA. 6Cells were resuspended at a concentration of 1 mL / mL in the test medium (IMDM, 1% BSA), and MnCl2 was added to a final concentration of 2 mM. 100,000 cells were then aliquoted into each well of a 96-well plate. The diluted antibody was then added to the cells, and the mixture was incubated at 37°C and 5% CO2 for 30 minutes. Blocking solution was decanted from the MAdCAM-1hFc-coated plate, and 100 μL / well of the pre-incubated HuT78 cell and mAb mixture was aliquoted into each well of the MAdCAM-1hFc-coated plate. The plate was rotated at 1,000 rpm for 1 minute and incubated at 37°C and 5% CO2 for 30 minutes. The adhered plate was gently decanted, and the plate was washed four times with 150 μL of washing buffer. After washing, 100 μL / well of the mixture (containing 50 μL of CellTiter-Glo reagent and 50 μL of test medium) was added to each well. The board was placed on a fixed-track oscillator for 2 minutes, then incubated at room temperature for 10 minutes. The emission from the board was read using a light-emitting board reader (Topcount, PerkinElmer). The emission signal was plotted in GraphPad Prism 7.0 using 4-parameter curve fitting analysis to determine the IC. 50 value.

[0327] 7.13.2. Results

[0328] Using plate-based and FACS-based assays, we tested the ability of Ab-h1.9d-WT to block the binding of the recombinant extracellular domain of the MAdCAM-1 protein to HuT78 cells and human lymphocytes (PBMCs) expressing α4β7.

[0329] ICs with speeds of 50 pM and 25 pM were obtained through FACS-based and board-based experiments, respectively. 50 value.

[0330] Furthermore, at 223pM IC 50 Ab-h1.9d-WT was observed to block the binding of MAdCAM-1 to human blood-derived lymphocytes (Table 29).

[0331]

[0332] *Mean ± Standard Deviation; N = 3

[0333] These data demonstrate the strong inhibitory effect of Ab-h1.9d-WT on the MAdCAM-1 / α4β7 interaction.

[0334] 7.14. Example 14: Ab-h1.9d-WT blocks MAdCAM-1 co-stimulation of human primary CD4+ T cells

[0335] 7.14.1. Materials and Methods

[0336] Isolation of human PBMCs and CD4+ T cells

[0337] Human peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood collected from healthy donors. Human CD4+ T cells were then isolated from the PBMCs using a CD4 negative selection kit (Stem Cell Technologies).

[0338] CD4+ T cell activation and proliferation assay

[0339] 96-well flat-bottomed tissue culture plates were coated with 200 ng / well of anti-CD3 antibody (Biolegend) in HBSS and incubated overnight at 4°C. The next day, the anti-CD3-coated plates were washed once with HBSS and incubated at 37°C for 1 hour with 200 ng / well of MAdCAM-1 (R&Dsystems). After incubation, the plates were washed once with 200 μl of HBSS, and 50,000 CD4+ T cells were added to each well with or without 1 μg / ml test antibody. After culturing the cells at 37°C and 5% CO2 for 96 hours, the cells were washed and stained with Live-Dead Aqua (Thermo Fisher Scientific), followed by staining with cell activation markers anti-CD25 FITC (clone MA0251, BD Bioscience) and anti-Ki67 APC (Biolegend). Cells were analyzed by flow cytometry, and data were analyzed using FlowJo software. GraphPad Prism was used to plot and perform statistical analysis on data from multiple donors. Significance was determined using one-way ANOVA combined with the graph-based multiple comparison test. ****p<0.0001, **p=0.001–0.01.

[0340] 7.14.2. Results

[0341] Ab-h1.9d-WT blocks MAdCAM-1 co-stimulation of human primary CD4+ T cells.

[0342] MAdCAM-1-mediated gut homing of α4β7+CD4+ T cells plays a crucial role in HIV infection of GALT (gut-associated lymphoid tissue). In addition to this role, MAdCAM-1 has been reported to deliver co-stimulatory signals to human primary CD4+ T cells and promote HIV replication (Nawaz et al., *Mucosal Immunology*, 2018). Given that HIV infection and replication require metabolic activation of these cells, and that Ab-h1.9d-WT can block the binding of MAdCAM-1 to human lymphocytes with an IC50 value of 223 pM (Table 35), we evaluated whether Ab-h1.9d-WT could block MAdCAM-1 co-stimulatory signals on human primary CD4+ T cells, which in turn would inhibit MAdCAM-1-mediated viral replication in these cells.

[0343] When primary human CD4+ T cells from a representative healthy donor were incubated with a plate containing only anti-CD3 antibodies for 96 hours, 22.6% of the cells were activated, exhibiting the Ki67+CD25+ phenotype. Figure 17A When cells were incubated with plates conjugated with anti-CD3 and MAdCAM-1, 56.6% of CD4+ T cells were activated. This indicates that MAdCAM-1 delivers a co-stimulatory signal to CD4+ T cells mediated by interaction with cell surface α4β7. Adding Ab-h1.9d-WT to cells during a 96-hour incubation period reduced cell activation to 20.8%, a level comparable to that achieved with anti-CD3 alone, while the isotype control Ab had no inhibitory effect on cell activation. The data indicate that Ab-h1.9d-WT effectively and completely blocked the co-stimulatory signaling exerted by MAdCAM-1. This experiment was repeated with primary CD4 T cells from five other donors; data are summarized in […]. Figure 17B In the middle. And from Figure 17A Consistent with data from a representative donor, Ab-h1.9d-WT almost completely blocked MAdCAM-1 / α4β7-mediated CD4+ T cell co-stimulation, while the isotype control Ab showed no inhibitory effect.

[0344] 7.15. Example 15: VCAM-1 ligand blocking specificity of Ab-h1.9d-WT

[0345] 7.15.1. Materials and Methods

[0346] The effect of Ab-h1.9d-WT on α4β7 / VCAM-1 interaction was evaluated in a VCAM-1-mediated cell adhesion assay.

[0347] VCAM-1 ligand blocking assay

[0348] On day 1, use coating buffer (PBS w / o Ca). +2 / Mg +2 0.1% BSA) was used to coat a 96-well flat-bottom plate (Grener Biotech, catalog number 655077) overnight at 4°C with 100 μL of 20 μg / mL LVCAM-1hFc or a homologous control (final concentration 2 μg per well). On day 2, the plate was washed with 200 μL of wash buffer (PBS w / Ca). +2 / Mg +2 Wash the plate three times with 0.1% BSA, then use blocking buffer (PBS w / Ca) +2 / Mg +2 Blocked at 37°C for 1 hour or longer using 1% BSA. During the blocking incubation, dilutions of Ab-h1.9d-WT, Ab-nata, and isotype control were prepared, and HuT78 cells were harvested. Antibody was prepared at 4 μg / mL at a 2-fold initial concentration, followed by 1:4 serial dilutions in experimental medium (IMDM, 1% BSA). HuT78 cells were counted, washed, and divided at 2 x 10⁻⁶ cells / mL. 6 100,000 cells / mL were resuspended in the test medium, and MnCl2 was added to a final concentration of 2 mM. Cells were then aliquoted into each well of a 96-well plate. The diluted antibody was then added to the cells, and the mixture was incubated at 37°C and 5% CO2 for 30 minutes. The blocking solution was decanted from the VCAM-1 hFc-coated plate, and 100 μL of the pre-incubated HuT78 cell and mAb mixture was aliquoted into each well of the VCAM-1 hFc-coated plate. The plate was incubated at 37°C and 5% CO2 for 30 minutes, and then gently washed three times with washing buffer. After washing, 100 μL / well of the mixture (containing 50 μL of CellTiter-Glo reagent and 50 μL of test medium) was added to each well. The plate was placed on a oscillator for 2 minutes, and then incubated at room temperature for 10 minutes. The luminescence of the plate was read using a Topcount luminescent plate reader (PerkinElmer). The luminescence signal was plotted in GraphPad Prism 7.0 using 4-parameter curve fitting analysis to determine the IC. 50 value.

[0349] 7.15.2. Results

[0350] In addition to enabling intestinal homing of blood lymphocytes through α4β7 binding to MAdCAM-1, α4β7 can also bind to VCAM-1 expressed on endothelial cells (Table 30).

[0351]

[0352] Natazapine (Ab-naa), an anti-α4 mAb, blocks the binding of α4β7 and α4β1 to VCAM-1, causing progressive multifocal leukoencephalopathy (PML) by blocking the transport of circulating lymphocytes to the brain. Therefore, evaluating the effect of Ab-h1.9d-WT on the α4β7 / VCAM-1 interaction in a VCAM-1-mediated cell adhesion assay is a necessary safety parameter for studies using Ab-nata as a positive control. As expected, Ab-nata showed a mean IC50 of 56 pM. 50 The value blocked VCAM-1-mediated HuT78 cell adhesion. Conversely, Ab-h1.9d-WT did not show detectable blockade of VCAM-1-mediated HuT78 cell adhesion. Figure 18 ).

[0353] Although Ab-h1.9d-WT effectively and selectively blocks the α4β7 / MAdCAM-1 interaction, it does not show inhibition of the α4β7 / VCAM-1 interaction.

[0354] 7.16. Example 16: Binding affinity of Ab-h1.9d-WT to human and cynomolgus monkey FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa and FcRn

[0355] 7.16.1. Materials and Methods

[0356] The binding affinity of Ab-h1.9d-WT to a group of recombinant human and cynomolgus monkey FcγR extracellular domain (ECD) proteins was evaluated by BIAcore compared with the antibody IgG1 control (trastuzumab).

[0357] The binding of Ab-h1.9d-WT to human FcγR was also evaluated by flow cytometry using CHO-K1 cells engineered to express various cell surface human FcγRs.

[0358] The binding of Ab-h1.9d-WT to human and cynomolgus FcRn was evaluated by BIAcore at pH 6.0 and pH 7.4 using recombinant human and cynomolgus monkey FcRn ECD proteins (Table 31).

[0359]

[0360] N=3

[0361] Combined experiment on surface plasmon resonance (SPR) of FcγR1, FcγRIIa, FcγRIIb and FcγRIIIa in humans and cynomolgus monkeys.

[0362] The binding kinetics of Ab-h1.9d-WT for His-tagged human FcγR were determined by SPR measurements using anti-His capture at 25°C on a Biacore T200 instrument (GE Healthcare). Mouse anti-His antibody (R&D) diluted to approximately 25 μg / mL in 10 mM sodium acetate (pH 4.5) was immobilized on a CM5 biosensor chip using a standard amine conjugation kit according to the manufacturer's instructions. Unreacted portions of the biosensor surface were blocked with 1 M ethanolamine. Activated and inactivated surfaces on flow cell 1 served as references. Chip preparation and binding kinetic measurements were performed in test run buffer, HBS-EP+ (10 mM hydroxyethylpiperazine ethanesulfonic acid, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween 20). Human and cynomolgus monkey FcγR were then captured on flow cell 2 to achieve capture levels ranging from 250 to 500 RU. Inject Ab-h1.9d-WT samples into all flow cells at a flow rate of 50 μL / min for 1 to 5 minutes (1 minute for human and cynomolgus monkey FcγRIIb and FcγRIIa, 2 minutes for human FcγRIIIa, and 5 minutes for human and cynomolgus monkey FcγRI & FcγRIII). Analyte concentration ranges were 0.78 to 200 nM for human and cynomolgus monkey FcγRI and FcγRIII, 46.9 to 12000 nM for human and cynomolgus monkey FcγRII, and 7.8 to 4000 nM for FcγRIII (2-fold serial dilutions). Buffer was injected only for dual reference. Dissociation of bound FcγR was monitored for 1 to 5 minutes (1 minute for FcγRIIb and FcγRIIa, 3 minutes for FcγRIIIa, and 5 minutes for FcγRI). 100 mM HCl was injected into all eight channels at a flow rate of 100 μL / min for two seconds to regenerate the chip surface. Three experiments were performed using the same CM5 chip for each sample. The results from the three experiments were averaged.

[0363] Human FcγR1, FcγRIIa, FcγRIIb, FcγRIIIa cell binding assay

[0364] CHO-K1 cells expressing hFcγR were cultured at 150 cm⁻¹. 2 Growth in culture flasks, with specific amounts of fluorophores and CellTrace CFSE loaded according to the manufacturer's instructions. TM Reagents and CellTrace Violet TMReagents (Molecular Probes) were used to establish unique fluorescent footprints (barcoding method) for each cell line. Cell lines were mixed with different concentrations (0, 0.01, 0.1, 1, 10, 50, 100, and 250 μg / mL) of monomeric Ab-h1.9d-WT in RPMI 1640 / 2mM L-glutamine / 10% ultra-low IgG heat-inactivated FBS (binding medium) and incubated at 4°C for one hour. After incubation, cells were incubated in PBS (w / o Ca) at pH 7.4. +2 / Mg +2 The cells were washed twice with AF647-conjugated secondary antibody (F(ab′)2 goat anti-human IgG(H+L)) in binding medium at 4°C for 15 minutes to detect cell binding of Ab-h1.9d-WT. After incubation, the cells were rinsed with PBS (w / o Ca) at pH 7.4. +2 / Mg +2 Cells were washed twice. Cell surface fluorescence was detected and recorded using a flow cytometer (LSR-Fortessa). The recorded fluorescence data were analyzed using FlowJo software version 10 (Tristar), and the Ab-h1.9d-WT binding to CHO-K1 hFcγR cells was reported as the geometric mean of AF647 fluorescence (generating gMFI binding curves as a function of Ab-h1.9d-WT concentration).

[0365] Human-cynomolgus monkey FcRn surface plasmon bonding experiment

[0366] For FcRn binding analysis, Ab-h1.9d-WT was directly immobilized on the amine conjugate on the CM5 chip at a density of 750 RU, following the manufacturer's guidelines. Human and cynomolgus monkey FcRn recombinant proteins were injected into all flow cells at a flow rate of 50 μL / min at concentrations ranging from 5.5 to 12000 nM (3-fold serial dilutions) for one minute, followed by dissociation for one minute. Surface regeneration was achieved by injecting HBS-EP+pH 7.4 for 15 seconds. Samples were prepared and run in two run buffers: MES EP+pH 6.0 and HBS-EP+pH 7.4. Three experiments were performed for each sample (in duplicate) using a different CM5 chip. The results from these three experiments were averaged. Data on the binding of human FcγRI, FcγRIIIa (F158), FcγRIIIa (V158), and cynomolgus monkey FcγRI, FcγRIII to all samples were fitted to a 1:1 global kinetic model with a fixed Rmax. Data on the binding of humans, FcγRIIb, FcγRIIa(H131), FcγRIIa(R131), cynomolgus monkeys FcγRIIa, FcγRIIb, and FcRn to all samples were fitted to a steady-state affinity model. Biacore T200 evaluation software version 2.0 was used to fit the FcγR and FcRn data.

[0367] 7.16.2. Results

[0368] Human-cynomolgus monkey FcγR1, FcγRIIa, FcγRIIb and FcγRIIIa binding

[0369] Tables 32 (for humans) and 33 (for cynomolgus monkeys) summarize the combined kinetic parameters.

[0370]

[0371] N=3

[0372] Ab-h1.9d-WT and trastuzumab exhibit similar measurable binding affinity for both hFcγRI and hFcγRII(H131), with weaker binding to the hFcγRII(R131) and hFcγRIIb receptors. Ab-h1.9d-WT and trastuzumab also show measurable binding affinity for hFcγRIIIa(F158 / V158), with higher affinity for the V158 polymorphic variant as expected.

[0373]

[0374] N=3

[0375] Although both Ab-h1.9d-WT and trastuzumab showed binding to cynomolgus FcγRI and cynomolgus FcγRIII, measurable binding parameters for cynomolgus FcγRIIa and FcγRII receptors could not be determined, possibly because their binding to these receptors is weak.

[0376] Human FcγR1, FcγRIIa, FcγRIIb, FcγRIIIa cell binding assay

[0377] Ab-h1.9d-WT showed the highest binding to human FcγRI and FcγRIIIa(V176) polymorphic variants, but relatively low binding to other human FcγRs [FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa(F176), and FcγRIIIb]. Figures 19A to 19B ).

[0378] Human-cynomolgus monkey FcRn surface plasmon bonding experiment

[0379] Ab-h1.9d-WT showed measurable binding to human and cynomolgus monkey FcRn under acidic conditions (pH 6.0), but no measurable binding at neutral pH (pH 7.4) (Table 34). The FcRn binding characteristics were comparable to the control (trastuzumab).

[0380]

[0381] N=3

[0382] 7.17. Example 17: In vitro ADCC, ADCP and CDC activities of Ab-h1.9d-WT

[0383] 7.17.1. Materials and Methods

[0384] The in vitro ADCC and ADCP activities of Ab-h1.9d-WT were evaluated using RPMI 8866 cells expressing naïve α4β7 / CD20 as target cells and Jurkat cells expressing the reporter gene hFcγRIIIa (V158) or hFcγRIIa (H131) as effector cells. This Jurkat cell line possesses an NFAT response element that drives firefly luciferase expression as a reporter gene. Ab-Ritu, an anti-CD20 mAb, was used as a positive control in these assays.

[0385] In addition, HuT78 cells expressing α4β7 / CD52 were used as targets, human primary NK cells as effectors, and Campas (anti-CD52) as a positive control antibody to evaluate Ab-h1.9d-WT in a cytotoxic ADCC assay.

[0386] ADCC reporter gene assay

[0387] RPMI 8866 cells targeting α4β7 were grown and maintained in medium (RPMI 1640, 2 mM L-glutamine, and 10% FBS). Logarithmic growth phase cells were collected, counted, washed, and cultured at 6 x 10⁻⁶ cells / year. 5 Resuspend the stock solution at 1 cell / mL in test medium (RPMI 1640 containing low IgG serum) and incubate at 37°C and 5% CO2 until ready for use. Prepare Ab-h1.9d-WT and control mAbs at 3 times the initial concentration of 30 μg / mL, and then serially dilute 1:100 (2-point) in Coster 3956 dilution plates. According to the plate layout, mix antibody (25 μL) with an equal volume of target RPMI 8866 cells (25 μL) in duplicate. Effector Jurkat cells (stable expression of human FcγRIIIa V158 variant and driver from Promega) were also prepared. TM The NFAT response element expressed by firefly luciferase was rapidly thawed and adjusted to 3 x 10⁻⁶ in the experimental medium. 6 Cells / mL. Jurkat effector (25 μL) was then added to 96-well plates containing RPMI 8866 target and antibody. Control wells included separate culture medium, separate effector (E) and target (T), E+T, E+mAb (30 μg / mL), or T+mAb (30 μg / mL). All wells were adjusted to 75 μL / well according to the plate layout. The final cell count was 75,000 Jurkat effector cells / well and 15,000 RPMI 8866 target cells / well, corresponding to an E:T ratio of 5:1. The final antibody concentrations per well were 67 nM (10 μg / mL), 0.67 nM (0.1 μg / mL), and 0.0067 nM (0.001 μg / mL). The plates were incubated at 37°C and 5% CO2 for 6 hours, during which time Bio-Glo was added before use. TM Equilibrate the buffer and substrate (catalog number 7110) to room temperature. At the end of incubation, reconstitute the Bio-Glo substrate with buffer to form an enzyme / substrate solution (Bio-Glo reagent). Add an equal volume of 75 μL / well of Bio-Glo to all wells. Then incubate the plate at room temperature for 10 minutes. Read the luminescence on the plate using a luminescence plate reader (Topcount, PerkinElmer). Plot the luminescence signal as RLU using GraphPadPrism 7.0 software.

[0388] ADCP reporter gene assay

[0389] RPMI 8866 cells targeting α4β7 were grown and maintained in medium (RPMI 1640, 2 mM L-glutamine, and 10% FBS). Logarithmic growth phase cells were collected, counted, washed, and cultured at 2 x 10⁻⁶ cells / year. 5 Resuspend the stock solution at 100 cells / mL in test medium (RPMI 1640 containing low IgG serum) and incubate at 37°C and 5% CO2 until ready for use. Prepare Ab-h1.9d-WT and control mAbs at an initial concentration of 30 μg / mL (3x), and then serially dilute 1:100 (2-point) in Coster 3956 dilution plates. According to the plate layout, mix antibody (25 μL) with an equal volume of target cells (25 μL) in duplicate. Effector Jurkat cells (stable expression of human FcγRIIa H131 variant and driver cells derived from Promega) were used. TM The NFAT response element expressed by firefly luciferase was rapidly thawed and adjusted to 1x10 in the experimental medium. 6 Cells / mL. Jurkat effector (25 μL) was then added to 96-well plates containing RPMI 8866 target and antibody. Control wells included separate culture medium, separate effector (E) and target (T), E+T, E+mAb (30 μg / mL), or T+mAb (30 μg / mL). All wells were adjusted to 75 μL / well according to the plate layout. The final cell count was 25,000 Jurkat effector cells / well and 5,000 target cells / well, corresponding to an E:T ratio of 5:1. The final antibody concentrations per well were 67 nM (10 μg / mL), 0.67 nM (0.1 μg / mL), and 0.0067 nM (0.001 μg / mL). The plates were incubated at 37°C and 5% CO2 for 6 hours, during which time Bio-Glo was added before use. TM Equilibrate the buffer and substrate (catalog number 7110) to room temperature. At the end of incubation, reconstitute the Bio-Glo substrate with buffer to form the enzyme / substrate solution (Bio-Glo reagent). Add an equal volume of 75 μL / well of Bio-Glo to all wells. Then incubate the plate at room temperature for 10 minutes. Read the luminescence on the plate using a luminescence plate reader (Topcount, PerkinElmer). Plot the luminescence signal as RLU using GraphPad Prism 7.0 software.

[0390] CDC Trial

[0391] RPMI 8866 cells were grown and maintained in medium (RPMI 1640, 2 mM L-glutamine, and 10% FBS). Logarithmic growth phase cells were collected, counted, washed, and packaged at 4 x 10⁻⁶ cells / day. 6Resuspend cells / mL of stock solution in test medium (RPMI 1640 minus phenol red, catalog number 11835-030) and incubate at 37°C and 5% CO2 until ready for use. Prepare Ab-h1.9d-WT and control mAbs at 3 times the initial concentration of 45 μg / mL and 0.45 μg / mL in Costa 3956 dilution plates. Thaw human donor serum (HMN19169 and HMN19170) with cold running water and immediately place on ice. Add antibody, control (25 μL), and culture medium to test plates (Costar 3599). Mix donor serum (25 μL each), target cells (25 μL), and diluted mAb (25 μL) to a final volume of 75 μL per well, each well containing 33% serum complement, 1 x 10-1 5 Cells and 15 μg / mL mAb were added. The plates were then incubated at 37°C and 5% CO2 for 2 hours. After incubation, 1.5 mg / mL of 5-fold stock solution of cell-permeable dye (Sigma; Resazurin Sodium Salt) was diluted 1:5 in DPBS and 25 μL of dye was added to each well. The plates were incubated for another 16 hours, and the absorbance (545 / 600) was read using a Clarostar plate reader. The percentage of target-specific cell lysis was calculated in Excel using the following formula: 100 - 100 x [(absorbance with mAb) / (control absorbance)]; the results were plotted using GraphPad Prism 7.0 software.

[0392] ADCC Cytotoxicity Assay

[0393] Harvest HuT78 cells expressing target α4β7 and use PBS (w / o Ca +2 / Mg +2 Wash twice with 1% BSA and 1x10 7 Cells were resuspended in PBS at a final concentration of 2 μM and labeled with CFSE for 8 minutes at room temperature. After incubation, FBS was added at a final concentration of 10% to quench the label. Cells were washed twice with RPMI + 10% FBS medium, and then CFSE-labeled HuT78 cells were incubated with 100 μL of 2-fold concentration of Ab-h1.9d-WT or control antibody at 10 μg / mL in 96-well V-bottom plates at 37°C and 5% CO2 for 30 minutes. Subsequently, 100 μL of 2.5 x 10⁻⁶ cells / mL was added to the PBS. 5One NK (FcγRIIIaVl58+) effector cell (pre-incubated with 200 U / mL IL-2) was added to the target cells. The contents of the wells were thoroughly mixed, and then incubated at 37°C in a CO2 incubator for 5 hours. The NK and HuT78 cell mixture was washed twice with PBS and then flushed with PBS containing 1 μL FVD dye / mL (azide-free and protein-free) at a concentration of 1 x 10⁻⁶. 6 Cells were resuspended at 1 / mL and incubated at room temperature for 20 min. Cells were washed twice with FACS buffer, resuspended in 200 μL of PBS containing 0.5% PFA, and read on a FACS (Canto II, BD) plate. Flow cytometry data (FCS 3.0 file) were analyzed using FlowJo version 10 software. All HuT78 target cells (live and dead) were gated to determine the percentage of dead target cells in the total target cell population. The formula used for %ADCC calculation was %ADCC = 100 × [% of dead target cells in the (E+T+Ab) mixture - % of dead target cells in the (E+T) mixture] / [100 - % of dead target cells in the (E+T) mixture]. ADCC percentages were plotted using GraphPad Prism 7.0 software.

[0394] 7.17.2. Results

[0395] ADCC reporter gene activity, ADCP reporter gene activity and CDC

[0396] As expected, Ab-Ritu exhibited strong concentration-dependent in vitro ADCC and ADCP activities; however, Ab-h1.9d-WT and the isotype control did not show any of these activities at the three tested concentrations (10, 0.1, and 0.001 μg / mL). Figure 20A and Figure 20B For the three negative control assays—target and effector alone, target plus antibody, and effector plus antibody—only minimal signals were detected (data not shown). Ab-Ritu also demonstrated strong in vitro CDC activity against RPMI 8866 cells at 0.15 and 15 μg / mL (100 nM), while Ab-h1.9d-WT and the isotype control showed no CDC signal at the corresponding concentrations using two human serum donors. Figure 21 ).

[0397] ADCC cytotoxicity

[0398] In this in vitro assay, Ab-Alem exhibited strong cytotoxicity against target cells. Conversely, when tested using NK effector cells isolated from two different donors with the FcγRIIIaVl58 genotype, Ab-h1.9d-WT at a concentration of 10 μg / mL (67 nM) did not induce any in vitro cytotoxicity. Figure 22 Therefore, although Ab-h1.9d-WT binds to human FcγR as described above (Example 12), it does not induce undesirable Fc-mediated ADCC, ADCP, and CDC activities in vitro against uninfected α4β7+ cells.

[0399] 7.18. Example 18: Homology modeling of Ab-h1.9d-WT binding sites on the target

[0400] 7.18.1. Materials and Methods

[0401] The binding mode of Ab-h1.9d-WT to α4β7 was explored through homology modeling. The crystal structure of the recombinant human α4β7 extracellular domain protein complexed with another anti-α4β7 antibody, vedolizumab, has been published (Yu et al., *Journal of Cell Biology*, 2012). Based on this data and the unique sequence of the Fab region of Ab-h1.9d-WT, the binding mode of the candidate antibody was modeled compared to the benchmark antibodies vedolizumab and AMG181.

[0402] 7.18.2. Results

[0403] Consistent with in vitro characterization data, Ab-h1.9 (a humanized variant of hybridoma Ab-ml and the parent of Ab-h1.9d-WT) and the two benchmark mAbs primarily bind α4β7 by interacting with the β7 subunit but also (to a lesser extent) with the α4 subunit. This model explains their insufficient binding to α4β1 and very low binding to αEβ7. Interestingly, the model suggests a subtle difference between Ab-h1.9 and the two benchmark mAbs: Ab-h1.9 binds to slightly more residues on the α4 subunit. The apparent overlapping epitopes in the model predict that Ab-h1.9 and vedolizumab will compete for binding to their targets. Indeed, in FACS-based binding competition studies, Ab-mi was able to compete with Ab-Vedo, which binds to α4β7+ cells, indicating that they bind to similar binding epitopes (Table 13).

[0404] 7.19. Discussion

[0405] The expression levels of α4β7 on peripheral human CD4+ and CD8+ T cell subsets are comparable in HIV+ and HIV- individuals, suggesting that α4β7 expression in CD4+ T cells of HIV+ individuals can support α4β7 incorporation into germinating HIV viral particles.

[0406] Ab-h1.9d-WT is a potent anti-α4β7 antibody that can bind to α4β7 on the viral particle envelope of all laboratory-grown HIV strains and tested HIV patient samples. The immune complex formed by Ab-h1.9d-WT and HIV viral particles can bind to different FcγRs via its Fc domain, a step that allows it to be taken up by APCs via phagocytosis to induce the proposed “vaccination effect” for HIV control.

[0407] Although Ab-h1.9d-WT binds to HIV viral particles, it does not neutralize HIV infection, consistent with the view that α4β7 is not a viral receptor on host cells. By targeting the host protein α4β7 integrin on the HIV viral envelope, Ab-h1.9d-WT exhibits a higher resistance barrier compared to other antibodies (e.g., broadly neutralizing HIV antibodies) that target the HIV-encoded gp120 / 41 glycoprotein in the viral envelope.

[0408] Ab-h1.9d-WT can disrupt the interaction between α4β7 and its ligands such as MadCAM-1 or HIV gp120 through a Fab-dependent mechanism, inhibiting CD4 T cell co-stimulation mediated by MadCAM-1 and gp120, and potentially suppressing HIV replication in these stimulated cells.

[0409] Ab-h1.9d-WT can potentially inhibit intercellular HIV transmission through a Fab-mediated mechanism by its ability to disrupt the interaction between α4β7 and HIV gp120.

[0410] Compared to Ab-h1.9d-WT, Ab-Vedo exhibited lower activity in capturing HIV viral particles and disrupting the interaction between α4β7 and HIV gp120. Furthermore, although Ab-Vedo was able to bind to HIV viral particles to form immune complexes, these immune complexes bound to FcγR with a much lower affinity than the complexes formed by Ab-h1.9d-WT due to engineered mutations in the Ab-Vedo Fc domain that reduced Fc function.

[0411] Vedolizumab demonstrated moderate efficacy in two clinical studies investigating HIV. This efficacy can be attributed to a Fab-dependent mechanism of action (e.g., the antibody's binding to α4β7 disrupts its interaction with its ligands such as MAdCAM-1 and HIV gp120, thereby inhibiting CD4 T cell co-stimulation and HIV replication in these stimulated cells, as well as intercellular viral transmission), rather than an Fc-dependent mechanism of action. Vedolizumab's reduced affinity for FcγR renders it defective in mediating an Fc-dependent mechanism. In contrast, Ab-h1.9d-WT, with its intact Fc function, may positively differentiate itself from vedolizumab by its ability to induce persistent HIV viral suppression through its Fc-dependent mechanism of action. The binding of the immune complex formed by HIV viral particles and the anti-α4β7 antibody (with an intact Fc domain) to FcγR on the APC is essential for inducing novel and durable HIV-specific immune responses (vaccination efficacy). In fact, Ab-h1.9d-WT can mediate the uptake of α4β7-coated beads or α4β7-expressing GFP+VLPs (virus-like particles) in THP-1 cells in an α4β7- and Fc-dependent manner. In summary, Ab-h1.9d-WT exhibits activity in several proposed HIV control mechanisms, including both Fc-dependent and Fab-dependent ones. Therefore, Ab-h1.9d-WT is expected to be a more effective agent than vedolizumab for sustained reduction of HIV viral load due to its higher affinity for α4β7 and its intact Fc function inducing a “vaccination effect.”

[0412] Table 35 summarizes the key properties of Ab-h1.9d-WT after comprehensive in vitro characterization.

[0413]

[0414] Ab-h1.9d-WT is an antagonistic anti-α4β7 human IgG1 / k monoclonal antibody that binds to α4β7 but not α4β1 and binds to αEβ7 minimally. Ab-h1.9d-WT binds strongly to both human and cynomolgus monkey CD4+ and CD8+ T subsets, indicating excellent cynomolgus monkey binding cross-reactivity. However, Ab-h1.9d-WT does not bind to rodent PBMCs. Ab-h1.9d-WT potently and selectively blocks the α4β7 / MAdCAM-1 interaction without inhibiting the α4β7 / VCAM-1 interaction. Ab-h1.9d-WT blocks MAdCAM-1-mediated co-stimulation of human primary CD4+ T cells. As expected against human IgG1, Ab-h1.9d-WT binds to human FcγR (a necessary prerequisite for Fc-mediated “vaccination action” in vivo) without triggering ADCC, ADCP, and CDC activity against uninfected α4β7+ cells in vitro. The lack of in vitro Fc effector activity in Ab-h1.9d-WT can be partially explained by reduced cell surface α4β7 expression due to antibody-induced target internalization. Additionally, Ab-h1.9d-WT can mediate the uptake of α4β7-coated beads or α4β7-expressing VLPs (virus-like particles) in THP-1 cells in both α4β7-dependent and Fc-dependent manner. Ab-h1.9d-WT exhibits the expected in vitro pharmacological properties required for a clinical candidate.

[0415] As provided in this disclosure, Ab-h1.9d-WT is an effective α4β7 selective antagonist that differs from and is an improvement upon vedolizumab. Key properties of Ab-h1.9d-WT compared to Ab-Vedo are shown in Tables 36 to 40 and summarized in Table 41.

[0416]

[0417]

[0418] Human PBMC = 3 donors

[0419]

[0420] Crab-eating macaques PBMC = 5 donors

[0421] CD4+ initial = CD4+CD45RA+CCR7+ cells, CD4+ memory = CD4+CD45RA- cells

[0422] CD8+ initial = CD8+CD45RA+CCR7+ cell, CD8+ memory = CD8+CD45RA- cell

[0423] Table 39 – Binding affinity of Ab-h1.9d-WT to human FcγR by BIAcore compared to Ab-Vedo.

[0424]

[0425] N=1

[0426] Table 40 – Binding affinity of Ab-h1.9d-WT to FcγR in cynomolgus monkeys by BIAcore versus Ab-Vedo.

[0427]

[0428] N=1

[0429] Table 41 – Key properties of Ab-h1.9d-WT compared to Ab-Vedo.

[0430]

[0431] 1 EC50 and IC50 values ​​are based on ≥3 independent experiments.

[0432] 2 Combined ECS0 values ​​based on PBMCs isolated from ≥3 donors

[0433] Key parameters of Ab-h1.9d-WT, such as its superior binding affinity for α4β7 and its ability to bind to human FcγR without triggering Fc-mediated effector function, are key differentiating factors from vedolizumab, and these characteristics are expected to drive improved potency compared to vedolizumab. Ab-h1.9d-WT also possesses the in vitro pharmacological properties required for an anti-α4β7 clinical candidate.

[0434] 8. Exemplary Embodiment

[0435] Although various specific embodiments have been illustrated and described, and some are shown below as examples, it should be understood that various changes can be made without departing from the spirit and scope of the invention.

[0436] 1. An anti-human α4β7 antibody comprising (i) a VH chain region containing three CDRs; and (ii) a VL chain region containing three CDRs, wherein:

[0437] VH CDR#1 is GFNIKNTYMH (SEQ ID NO: 72);

[0438] VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO: 73);

[0439] VH CDR#3 is VDV (SEQ ID NO: 74);

[0440] VL CDR#1 is HASQDISDNIG (SEQ ID NO: 75);

[0441] VL CDR#2 is HGTNLED (SEQ ID NO: 76); and

[0442] VL CDR#3 is VQYAQFPWT (SEQ ID NO: 77).

[0443] 2. The anti-human α4β7 antibody according to Example 1, comprising:

[0444] VH Chain Section:

[0445] EVQLVQSGAEVKKPGSSVKVSCKASGFNIKNTYMHWVRQAPGQGLEWIGRIDPAKGHTEYAPKFLGRVTITADESTNTAYMELSSLRSEDTAVYYCYYVDVWGQGTTVTVSS (SEQ ID NO: 70); and

[0446] VL Chain Zone:

[0447] DIQMTQSPSSSLSASVGDRVTITCHASQDISDNIGWLQQKPGKSFKLLIYHGTNLEDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKVEIK (SEQ ID NO: 71).

[0448] 3. The anti-human α4β7 antibody according to Example 1 or 2 is humanized.

[0449] 4. The anti-human α4β7 antibody according to any one of Examples 1 to 3 is IgG.

[0450] 5. The anti-human α4β7 antibody according to any one of Examples 1 to 4, comprising a constant region of the κ light chain.

[0451] 6. The anti-human α4β7 antibody according to any one of Examples 1 to 5 is IgG1.

[0452] 7. The anti-human α4β7 antibody according to any one of Examples 1 to 6, comprising a variant CH3 domain having amino acid substitutions D356E and L358M.

[0453] 8. The anti-human α4β7 antibody according to any one of Examples 1 to 7, comprising a heavy chain having an amino acid sequence having SEQ ID NO: 92 or SEQ ID NO: 93 and a light chain having an amino acid sequence having SEQ ID NO: 100.

[0454] 9. The anti-human α4β7 antibody according to any one of Examples 1 to 8, comprising a variant CH2 domain having amino acid substitutions for L234A and / or L235A.

[0455] 10. The anti-human α4β7 antibody according to any one of Examples 1 to 9, comprising a variant CH2 domain having an amino acid substitution T250Q and / or a variant CH3 domain having an amino acid substitution M428L.

[0456] 11. A polynucleotide comprising a nucleotide sequence encoding an anti-human α4β7 antibody, wherein the antibody comprises (i) a VH region comprising three CDRs; and (ii) a VL region comprising three CDRs, wherein:

[0457] VH CDR#1 is GFNIKNTYMH (SEQ ID NO: 72);

[0458] VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO: 73);

[0459] VH CDR#3 is VDV (SEQ ID NO: 74);

[0460] VL CDR#1 is HASQDISDNIG (SEQ ID NO: 75);

[0461] VL CDR#2 is HGTNLED (SEQ ID NO: 76); and

[0462] VL CDR#3 is VQYAQFPWT (SEQ ID NO: 77).

[0463] 12. An expression vector comprising the polynucleotide described in Example 11.

[0464] 13. A eukaryotic host cell transfected with the vector described in Example 12.

[0465] 14. A eukaryotic host cell engineered to express the polynucleotides described in Example 11.

[0466] 15. The eukaryotic host cell according to Example 13 or 14 is a mammalian host cell.

[0467] 16. A method for producing anti-human α4β7 antibody, comprising: (a) culturing the eukaryotic host cells described in Example 15 and (b) recovering the anti-human α4β7 antibody.

[0468] 17. A prokaryotic host cell transformed using the vector described in Example 12.

[0469] 18. A prokaryotic host cell engineered to express the polynucleotides described in Example 17.

[0470] 19. The prokaryotic host cell according to Example 18 is a bacterial host cell.

[0471] 20. A method for producing an anti-human α4β7 antibody, comprising: (a) culturing the prokaryotic host cells described in Example 19, and (b) recovering the anti-human α4β7 antibody.

[0472] 21. A method for inducing viral suppression of HIV infection in a subject infected with HIV, comprising administering to the subject an amount of the anti-human α4β7 antibody described in any one of Examples 1 to 10.

[0473] 22. The method according to Example 21, wherein viral suppression is immune-mediated.

[0474] 23. A method of treating HIV infection in a subject infected with HIV, comprising administering to the subject an amount of the anti-human α4β7 antibody described in any one of Examples 1 to 10.

[0475] 24. An anti-human α4β7 antibody that inhibits HIV.

[0476] 25. The anti-human α4β7 antibody according to Example 24 inhibits HIV replication and / or HIV infection.

[0477] 26. The anti-human α4β7 antibody according to Example 24, which inactivates and / or reduces the activation of human α4β7 on cells expressing human α4β7.

[0478] 27. The anti-human α4β7 antibody according to Example 24 induces the internalization of human α4β7 on cells expressing human α4β7.

[0479] 28. The anti-human α4β7 antibody according to Example 24 inhibits CD4 T cell co-stimulation.

[0480] 29. The anti-human α4β7 antibody according to Example 28, wherein CD4 T cell co-stimulation is mediated by MAdCAM-1 or HIV gp120.

[0481] 30. The anti-human α4β7 antibody according to Example 25 inhibits HIV replication in CD4 T cells.

[0482] 31. The anti-human α4β7 antibody according to Example 30, wherein the CD4 T cells are MAdCAM-1 stimulated CD4 T cells or HIV gpl20 stimulated CD4 T cells.

[0483] 32. The anti-human α4β7 antibody according to Example 24 disrupts the interaction between α4β7 and at least one of its ligands.

[0484] 33. The anti-human α4β7 antibody according to Example 32, wherein the α4β7 ligand is MAdCAM-1.

[0485] 34. The anti-human α4β7 antibody according to Example 32, wherein the α4β7 ligand is HIV gp120.

[0486] 35. The anti-human α4β7 antibody according to Example 34 inhibits gp120-mediated HIV intercellular transmission.

[0487] 36. The anti-human α4β7 antibody according to Example 24, which binds to HIV viral particles.

[0488] 37. The anti-human α4β7 antibody according to Example 36, wherein the antibody binds to HIV viral particles to form an immune complex.

[0489] 38. The anti-human α4β7 antibody according to Example 37, wherein the immune complex binds to FcγR on the cell.

[0490] 39. The anti-human α4β7 antibody according to Example 37, wherein the immune complex binds to FcγR on antigen-presenting cells (APCs).

[0491] 40. The anti-human α4β7 antibody according to Example 39, wherein the immune complex is taken up by APC via phagocytosis.

[0492] 41. The anti-human α4β7 antibody according to Example 40 induces an HIV-specific immune response.

[0493] 42. The anti-human α4β7 antibody according to Example 40 or 41 induces HIV vaccination.

[0494] 43. The anti-human α4β7 antibody according to Example 41, wherein an HIV-specific immune response leads to viral control of HIV in HIV-infected individuals.

[0495] 44. The anti-human α4β7 antibody according to Example 43, wherein viral control leads to a reduction in viral load.

[0496] 45. The anti-human α4β7 antibody according to Example 43, wherein viral control results in a lower viral load set point.

[0497] 46. ​​The anti-human α4β7 antibody according to Example 43, wherein viral control leads to delayed viral rebound after interruption of antiretroviral therapy (ATI).

[0498] 47. The anti-human α4β7 antibody according to any one of Examples 24 to 46, having a set of six complementarity-determining regions (CDRs) or variable heavy chain regions and variable light chain regions from the antibody, said antibody being selected from the following: Ab-m1, Ab-c1, Ab-h1.1, Ab-h1.2, Ab-h1.3, Ab-h1.4, Ab-h1.5, Ab-h1.6, Ab-h1.7, Ab-h1.8, Ab-h1.9, Ab-h1.9a, Ab-h1.9b, Ab-h1.9c, Ab-h1.gd, or Ab-h1.9e.

[0499] 48. The anti-human α4β7 antibody according to any one of Examples 1 to 10 inhibits HIV.

[0500] 49. The anti-human α4β7 antibody according to Example 48, which inhibits HIV replication and / or HIV infection.

[0501] 50. The anti-human α4β7 antibody according to Example 48, which inactivates and / or reduces the activation of human α4β7 on cells expressing human α4β7.

[0502] 51. The anti-human α4β7 antibody according to Example 48 induces the internalization of human α4β7 on cells expressing human α4β7.

[0503] 52. The anti-human α4β7 antibody according to Example 48 inhibits CD4 T cell co-stimulation.

[0504] 53. The anti-human α4β7 antibody according to Example 52, wherein CD4 T cell co-stimulation is mediated by MAdCAM-1 or HIV gp120.

[0505] 54. The anti-human α4β7 antibody according to Example 49 inhibits HIV replication in CD4 T cells.

[0506] 55. The anti-human α4β7 antibody according to Example 54, wherein the CD4 T cells are MAdCAM-1 stimulated CD4 T cells or HIV gp120 stimulated CD4 T cells.

[0507] 56. The anti-human α4β7 antibody according to Example 48 disrupts the interaction between α4β7 and at least one of its ligands.

[0508] 57. The anti-human α4β7 antibody according to Example 56, wherein the α4β7 ligand is MAdCAM-1.

[0509] 58. The anti-human α4β7 antibody according to Example 56, wherein the α4β7 ligand is HIV gp120.

[0510] 59. The anti-human α4β7 antibody according to Example 58 inhibits gp120-mediated HIV intercellular transmission.

[0511] 60. The anti-human α4β7 antibody according to Example 48, which binds to HIV viral particles.

[0512] 61. The anti-human α4β7 antibody according to Example 60, wherein the antibody binds to HIV viral particles to form an immune complex.

[0513] 62. The anti-human α4β7 antibody according to Example 61, wherein the immune complex binds to FcγR on the cell.

[0514] 63. The anti-human α4β7 antibody according to Example 61, wherein the immune complex binds to FcγR on antigen-presenting cells (APCs).

[0515] 64. The anti-human α4β7 antibody according to Example 63, wherein the immune complex is taken up by APC via phagocytosis.

[0516] 65. The anti-human α4β7 antibody according to Example 64 induces an HIV-specific immune response.

[0517] 66. The anti-human α4β7 antibody according to Example 64 or 65 induces HIV vaccination.

[0518] 67. The anti-human α4β7 antibody according to Example 64 or 65, wherein an HIV-specific immune response leads to viral control of HIV in an HIV-infected individual.

[0519] 68. The anti-human α4β7 antibody according to Example 67, wherein viral control leads to a reduction in viral load.

[0520] 69. The anti-human α4β7 antibody according to Example 67, wherein viral control results in a lower viral load set point.

[0521] 70. The anti-human α4β7 antibody according to Example 67, wherein viral control leads to delayed viral rebound after interruption of antiretroviral therapy (ATI).

[0522] 71. A pharmaceutical composition comprising the antibody described in any one of the foregoing embodiments. sequence list <110> AbbVie Inc. <120> Anti-α4β7 antibody <130> 397835-483WO (184835) <150> US 63 / 052,933 <151> 2020-07-16 <160> 100 <170> PatentIn version 3.5 <210> 1 <211> 1032 <212> PRT <213> Humans <400> 1 Met Ala Trp Glu Ala Arg Arg Glu Pro Gly Pro Arg Arg Ala Ala Val 1 5 10 15 Arg Glu Thr Val Met Leu Leu Leu Cys Leu Gly Val Pro Thr Gly Arg 20 25 30 Pro Tyr Asn Val Asp Thr Glu Ser Ala Leu Leu Tyr Gln Gly Pro His 35 40 45 Asn Thr Leu Phe Gly Tyr Ser Val Val Leu His Ser His Gly Ala Asn 50 55 60 Arg Trp Leu Leu Val Gly Ala Pro Thr Ala Asn Trp Leu Ala Asn Ala 65 70 75 80 Ser Val Ile Asn Pro Gly Ala Ile Tyr Arg Cys Arg Ile Gly Lys Asn 85 90 95 Pro Gly Gln Thr Cys Glu Gln Leu Gln Leu Gly Ser Pro Asn Gly Glu 100 105 110 Pro Cys Gly Lys Thr Cys Leu Glu Glu Arg Asp Asn Gln Trp Leu Gly 115 120 125 Val Thr Leu Ser Arg Gln Pro Gly Glu Asn Gly Ser Ile Val Thr Cys 130 135 140 Gly His Arg Trp Lys Asn Ile Phe Tyr Ile Lys Asn Glu Asn Lys Leu 145 150 155 160 Pro Thr Gly Gly Cys Tyr Gly Val Pro Pro Asp Leu Arg Thr Glu Leu 165 170 175 Ser Lys Arg Ile Ala Pro Cys Tyr Gln Asp Tyr Val Lys Lys Phe Gly 180 185 190 Glu Asn Phe Ala Ser Cys Gln Ala Gly Ile Ser Ser Phe Tyr Thr Lys 195 200 205 Asp Leu Ile Val Met Gly Ala Pro Gly Ser Ser Tyr Trp Thr Gly Ser 210 215 220 Leu Phe Val Tyr Asn Ile Thr Thr Asn Lys Tyr Lys Ala Phe Leu Asp 225 230 235 240 Lys Gln Asn Gln Val Lys Phe Gly Ser Tyr Leu Gly Tyr Ser Val Gly 245 250 255 Ala Gly His Phe Arg Ser Gln His Thr Thr Glu Val Val Gly Gly Ala 260 265 270 Pro Gln His Glu Gln Ile Gly Lys Ala Tyr Ile Phe Ser Ile Asp Glu 275 280 285 Lys Glu Leu Asn Ile Leu His Glu Met Lys Gly Lys Lys Leu Gly Ser 290 295 300 Tyr Phe Gly Ala Ser Val Cys Ala Val Asp Leu Asn Ala Asp Gly Phe 305 310 315 320 Ser Asp Leu Leu Val Gly Ala Pro Met Gln Ser Thr Ile Arg Glu Glu 325 330 335 Gly Arg Val Phe Val Tyr Ile Asn Ser Gly Ser Gly Ala Val Met Asn 340 345 350 Ala Met Glu Thr Asn Leu Val Gly Ser Asp Lys Tyr Ala Ala Arg Phe 355 360 365 Gly Glu Ser Ile Val Asn Leu Gly Asp Ile Asp Asn Asp Gly Phe Glu 370 375 380 Asp Val Ala Ile Gly Ala Pro Gln Glu Asp Asp Leu Gln Gly Ala Ile 385 390 395 400 Tyr Ile Tyr Asn Gly Arg Ala Asp Gly Ile Ser Ser Thr Phe Ser Gln 405 410 415 Arg Ile Glu Gly Leu Gln Ile Ser Lys Ser Leu Ser Met Phe Gly Gln 420 425 430 Ser Ile Ser Gly Gln Ile Asp Ala Asp Asn Asn Gly Tyr Val Asp Val 435 440 445 Ala Val Gly Ala Phe Arg Ser Asp Ser Ala Val Leu Leu Arg Thr Arg 450 455 460 Pro Val Val Ile Val Asp Ala Ser Leu Ser His Pro Glu Ser Val Asn 465 470 475 480 Arg Thr Lys Phe Asp Cys Val Glu Asn Gly Trp Pro Ser Val Cys Ile 485 490 495 Asp Leu Thr Leu Cys Phe Ser Tyr Lys Gly Lys Glu Val Pro Gly Tyr 500 505 510 Ile Val Leu Phe Tyr Asn Met Ser Leu Asp Val Asn Arg Lys Ala Glu 515 520 525 Ser Pro Pro Arg Phe Tyr Phe Ser Ser Asn Gly Thr Ser Asp Val Ile 530 535 540 Thr Gly Ser Ile Gln Val Ser Ser Arg Glu Ala Asn Cys Arg Thr His 545 550 555 560 Gln Ala Phe Met Arg Lys Asp Val Arg Asp Ile Leu Thr Pro Ile Gln 565 570 575 Ile Glu Ala Ala Tyr His Leu Gly Pro His Val Ile Ser Lys Arg Ser 580 585 590 Thr Glu Glu Phe Pro Pro Leu Gln Pro Ile Leu Gln Gln Lys Lys Glu 595 600 605 Lys Asp Ile Met Lys Lys Thr Ile Asn Phe Ala Arg Phe Cys Ala His 610 615 620 Glu Asn Cys Ser Ala Asp Leu Gln Val Ser Ala Lys Ile Gly Phe Leu 625 630 635 640 Lys Pro His Glu Asn Lys Thr Tyr Leu Ala Val Gly Ser Met Lys Thr 645 650 655 Leu Met Leu Asn Val Ser Leu Phe Asn Ala Gly Asp Asp Ala Tyr Glu 660 665 670 Thr Thr Leu His Val Lys Leu Pro Val Gly Leu Tyr Phe Ile Lys Ile 675 680 685 Leu Glu Leu Glu Glu Lys Gln Ile Asn Cys Glu Val Thr Asp Asn Ser 690 695 700 Gly Val Val Gln Leu Asp Cys Ser Ile Gly Tyr Ile Tyr Val Asp His 705 710 715 720 Leu Ser Arg Ile Asp Ile Ser Phe Leu Leu Asp Val Ser Ser Leu Ser 725 730 735 Arg Ala Glu Glu Asp Leu Ser Ile Thr Val His Ala Thr Cys Glu Asn 740 745 750 Glu Glu Glu Met Asp Asn Leu Lys His Ser Arg Val Thr Val Ala Ile 755 760 765 Pro Leu Lys Tyr Glu Val Lys Leu Thr Val His Gly Phe Val Asn Pro 770 775 780 Thr Ser Phe Val Tyr Gly Ser Asn Asp Glu Asn Glu Pro Glu Thr Cys 785 790 795 800 Met Val Glu Lys Met Asn Leu Thr Phe His Val Ile Asn Thr Gly Asn 805 810 815 Ser Met Ala Pro Asn Val Ser Val Glu Ile Met Val Pro Asn Ser Phe 820 825 830 Ser Pro Gln Thr Asp Lys Leu Phe Asn Ile Leu Asp Val Gln Thr Thr 835 840 845 Thr Gly Glu Cys His Phe Glu Asn Tyr Gln Arg Val Cys Ala Leu Glu 850 855 860 Gln Gln Lys Ser Ala Met Gln Thr Leu Lys Gly Ile Val Arg Phe Leu 865 870 875 880 Ser Lys Thr Asp Lys Arg Leu Leu Tyr Cys Ile Lys Ala Asp Pro His 885 890 895 Cys Leu Asn Phe Leu Cys Asn Phe Gly Lys Met Glu Ser Gly Lys Glu 900 905 910 Ala Ser Val His Ile Gln Leu Glu Gly Arg Pro Ser Ile Leu Glu Met 915 920 925 Asp Glu Thr Ser Ala Leu Lys Phe Glu Ile Arg Ala Thr Gly Phe Pro 930 935 940 Glu Pro Asn Pro Arg Val Ile Glu Leu Asn Lys Asp Glu Asn Val Ala 945 950 955 960 His Val Leu Leu Glu Gly Leu His His Gln Arg Pro Lys Arg Tyr Phe 965 970 975 Thr Ile Val Ile Ile Ser Ser Ser Leu Leu Gly Leu Ile Val Leu 980 985 990 Leu Leu Ile Ser Tyr Val Met Trp Lys Ala Gly Phe Phe Lys Arg Gln 995 1000 1005 Tyr Lys Ser Ile Leu Gln Glu Glu Asn Arg Arg Asp Ser Trp Ser 1010 1015 1020 Tyr Ile Asn Ser Lys Ser Asn Asp Asp 1025 1030 <210> 2 <211> 195 <212> PRT <213> human <400> 2 Met Ala Trp Glu Ala Arg Arg Glu Pro Gly Pro Arg Arg Ala Ala Val 1 5 10 15 Arg Glu Thr Val Met Leu Leu Leu Cys Leu Gly Val Pro Thr Gly Arg 20 25 30 Pro Tyr Asn Val Asp Thr Glu Ser Ala Leu Leu Tyr Gln Gly Pro His 35 40 45 Asn Thr Leu Phe Gly Tyr Ser Val Val Leu His Ser His Gly Ala Asn 50 55 60 Arg Trp Leu Leu Val Gly Ala Pro Thr Ala Asn Trp Leu Ala Asn Ala 65 70 75 80 Ser Val Ile Asn Pro Gly Ala Ile Tyr Arg Cys Arg Ile Gly Lys Asn 85 90 95 Pro Gly Gln Thr Cys Glu Gln Leu Gln Leu Gly Ser Pro Asn Gly Glu 100 105 110 Pro Cys Gly Lys Thr Cys Leu Glu Glu Arg Asp Asn Gln Trp Leu Gly 115 120 125 Val Thr Leu Ser Arg Gln Pro Gly Glu Asn Gly Ser Ile Val Thr Cys 130 135 140 Gly His Arg Trp Lys Asn Ile Phe Tyr Ile Lys Asn Glu Asn Lys Leu 145 150 155 160 Pro Thr Gly Gly Cys Tyr Gly Val Pro Pro Asp Leu Arg Thr Glu Leu 165 170 175 Ser Lys Arg Ile Ala Pro Cys Tyr Gln Gly Ser Ile Ser Lys Tyr Arg 180 185 190 Ala Arg Thr 195 <210> 3 <211> 798 <212> PRT <213> Human <400> 3 Met Val Ala Leu Pro Met Val Leu Val Leu Leu Leu Val Leu Ser Arg 1 5 10 15 Gly Glu Ser Glu Leu Asp Ala Lys Ile Pro Ser Thr Gly Asp Ala Thr 20 25 30 Glu Trp Arg Asn Pro His Leu Ser Met Leu Gly Ser Cys Gln Pro Ala 35 40 45 Pro Ser Cys Gln Lys Cys Ile Leu Ser His Pro Ser Cys Ala Trp Cys 50 55 60 Lys Gln Leu Asn Phe Thr Ala Ser Gly Glu Ala Glu Ala Arg Arg Cys 65 70 75 80 Ala Arg Arg Glu Glu Leu Leu Ala Arg Gly Cys Pro Leu Glu Glu Leu 85 90 95 Glu Glu Pro Arg Gly Gln Gln Glu Val Leu Gln Asp Gln Pro Leu Ser 100 105 110 Gln Gly Ala Arg Gly Glu Gly Ala Thr Gln Leu Ala Pro Gln Arg Val 115 120 125 Arg Val Thr Leu Arg Pro Gly Glu Pro Gln Gln Leu Gln Val Arg Phe 130 135 140 Leu Arg Ala Glu Gly Tyr Pro Val Asp Leu Tyr Tyr Leu Met Asp Leu 145 150 155 160 Ser Tyr Ser Met Lys Asp Asp Leu Glu Arg Val Arg Gln Leu Gly His 165 170 175 Ala Leu Leu Val Arg Leu Gln Glu Val Thr His Ser Val Arg Ile Gly 180 185 190 Phe Gly Ser Phe Val Asp Lys Thr Val Leu Pro Phe Val Ser Thr Val 195 200 205 Pro Ser Lys Leu Arg His Pro Cys Pro Thr Arg Leu Glu Arg Cys Gln 210 215 220 Ser Pro Phe Ser Phe His His Val Leu Ser Leu Thr Gly Asp Ala Gln 225 230 235 240 Ala Phe Glu Arg Glu Val Gly Arg Gln Ser Val Ser Gly Asn Leu Asp 245 250 255 Ser Pro Glu Gly Gly Phe Asp Ala Ile Leu Gln Ala Ala Leu Cys Gln 260 265 270 Glu Gln Ile Gly Trp Arg Asn Val Ser Arg Leu Leu Val Phe Thr Ser 275 280 285 Asp Asp Thr Phe His Thr Ala Gly Asp Gly Lys Leu Gly Gly Ile Phe 290 295 300 Met Pro Ser Asp Gly His Cys His Leu Asp Ser Asn Gly Leu Tyr Ser 305 310 315 320 Arg Ser Thr Glu Phe Asp Tyr Pro Ser Val Gly Gln Val Ala Gln Ala 325 330 335 Leu Ser Ala Ala Asn Ile Gln Pro Ile Phe Ala Val Thr Ser Ala Ala 340 345 350 Leu Pro Val Tyr Gln Glu Leu Ser Lys Leu Ile Pro Lys Ser Ala Val 355 360 365 Gly Glu Leu Ser Glu Asp Ser Ser Asn Val Val Gln Leu Ile Met Asp 370 375 380 Ala Tyr Asn Ser Leu Ser Ser Thr Val Thr Leu Glu His Ser Ser Leu 385 390 395 400 Pro Pro Gly Val His Ile Ser Tyr Glu Ser Gln Cys Glu Gly Pro Glu 405 410 415 Lys Arg Glu Gly Lys Ala Glu Asp Arg Gly Gln Cys Asn His Val Arg 420 425 430 Ile Asn Gln Thr Val Thr Phe Trp Val Ser Leu Gln Ala Thr His Cys 435 440 445 Leu Pro Glu Pro His Leu Leu Arg Leu Arg Ala Leu Gly Phe Ser Glu 450 455 460 Glu Leu Ile Val Glu Leu His Thr Leu Cys Asp Cys Asn Cys Ser Asp 465 470 475 480 Thr Gln Pro Gln Ala Pro His Cys Ser Asp Gly Gln Gly His Leu Gln 485 490 495 Cys Gly Val Cys Ser Cys Ala Pro Gly Arg Leu Gly Arg Leu Cys Glu 500 505 510 Cys Ser Val Ala Glu Leu Ser Ser Pro Asp Leu Glu Ser Gly Cys Arg 515 520 525 Ala Pro Asn Gly Thr Gly Pro Leu Cys Ser Gly Lys Gly His Cys Gln 530 535 540 Cys Gly Arg Cys Ser Cys Ser Gly Gln Ser Ser Gly His Leu Cys Glu 545 550 555 560 Cys Asp Asp Ala Ser Cys Glu Arg His Glu Gly Ile Leu Cys Gly Gly 565 570 575 Phe Gly Arg Cys Gln Cys Gly Val Cys His Cys His Ala Asn Arg Thr 580 585 590 Gly Arg Ala Cys Glu Cys Ser Gly Asp Met Asp Ser Cys Ile Ser Pro 595 600 605 Glu Gly Gly Leu Cys Ser Gly His Gly Arg Cys Lys Cys Asn Arg Cys 610 615 620 Gln Cys Leu Asp Gly Tyr Tyr Gly Ala Leu Cys Asp Gln Cys Pro Gly 625 630 635 640 Cys Lys Thr Pro Cys Glu Arg His Arg Asp Cys Ala Glu Cys Gly Ala 645 650 655 Phe Arg Thr Gly Pro Leu Ala Thr Asn Cys Ser Thr Ala Cys Ala His 660 665 670 Thr Asn Val Thr Leu Ala Leu Ala Pro Ile Leu Asp Asp Gly Trp Cys 675 680 685 Lys Glu Arg Thr Leu Asp Asn Gln Leu Phe Phe Phe Leu Val Glu Asp 690 695 700 Asp Ala Arg Gly Thr Val Val Leu Arg Val Arg Pro Gln Glu Lys Gly 705 710 715 720 Ala Asp His Thr Gln Ala Ile Val Leu Gly Cys Val Gly Gly Ile Val 725 730 735 Ala Val Gly Leu Gly Leu Val Leu Ala Tyr Arg Leu Ser Val Glu Ile 740 745 750 Tyr Asp Arg Arg Glu Tyr Ser Arg Phe Glu Lys Glu Gln Gln Gln Leu 755 760 765 Asn Trp Lys Gln Asp Ser Asn Pro Leu Tyr Lys Ser Ala Ile Thr Thr 770 775 780 Thr Ile Asn Pro Arg Phe Gln Glu Ala Asp Ser Pro Thr Leu 785 790 795 <210> 4 <211> 650 <212> PRT <213> humans <400> 4 Met Val Ala Leu Pro Met Val Leu Val Leu Leu Leu Leu Val Leu Ser Arg 1 5 10 15 Gly Glu Ser Glu Leu Asp Ala Lys Ile Pro Ser Thr Gly Asp Ala Thr 20 25 30 Glu Trp Arg Asn Pro His Leu Ser Met Leu Gly Ser Cys Gln Pro Ala 35 40 45 Pro Ser Cys Gln Lys Cys Ile Leu Ser His Pro Ser Cys Ala Trp Cys 50 55 60 Lys Gln Leu Asn Phe Thr Ala Ser Gly Glu Ala Glu Ala Arg Arg Cys 65 70 75 80 Ala Arg Arg Glu Glu Leu Leu Ala Arg Gly Cys Pro Leu Glu Glu Leu 85 90 95 Glu Glu Pro Arg Gly Gln Gln Glu Val Leu Gln Asp Gln Pro Leu Ser 100 105 110 Gln Gly Ala Arg Gly Glu Gly Ala Thr Gln Leu Ala Pro Gln Arg Val 115 120 125 Arg Val Thr Leu Arg Pro Gly Glu Pro Gln Gln Leu Gln Val Arg Phe 130 135 140 Leu Arg Ala Glu Gly Tyr Pro Val Asp Leu Tyr Tyr Leu Met Asp Leu 145 150 155 160 Ser Tyr Ser Met Lys Asp Asp Leu Glu Arg Val Arg Gln Leu Gly His 165 170 175 Ala Leu Leu Val Arg Leu Gln Glu Val Thr His Ser Val Arg Ile Gly 180 185 190 Phe Gly Ser Phe Val Asp Lys Thr Val Leu Pro Phe Val Ser Thr Val 195 200 205 Pro Ser Lys Leu Arg His Pro Cys Pro Thr Arg Leu Glu Arg Cys Gln 210 215 220 Ser Pro Phe Ser Phe His His Val Leu Ser Leu Thr Gly Asp Ala Gln 225 230 235 240 Ala Phe Glu Arg Glu Val Gly Arg Gln Ser Val Ser Gly Asn Leu Asp 245 250 255 Ser Pro Glu Gly Gly Phe Asp Ala Ile Leu Gln Ala Ala Leu Cys Gln 260 265 270 Glu Gln Ile Gly Trp Arg Asn Val Ser Arg Leu Leu Val Phe Thr Ser 275 280 285 Asp Asp Thr Phe His Thr Ala Gly Asp Gly Lys Leu Gly Gly Ile Phe 290 295 300 Met Pro Ser Asp Gly His Cys His Leu Asp Ser Asn Gly Leu Tyr Ser 305 310 315 320 Arg Ser Thr Glu Phe Asp Tyr Pro Ser Val Gly Gln Val Ala Gln Ala 325 330 335 Leu Ser Ala Ala Asn Ile Gln Pro Ile Phe Ala Val Thr Ser Ala Ala 340 345 350 Leu Pro Val Tyr Gln Glu Leu Ser Lys Leu Ile Pro Lys Ser Ala Val 355 360 365 Gly Glu Leu Ser Glu Asp Ser Ser Asn Val Val Gln Leu Ile Met Asp 370 375 380 Ala Tyr Asn Ser Leu Ser Ser Thr Val Thr Leu Glu His Ser Ser Leu 385 390 395 400 Pro Pro Gly Val His Ile Ser Tyr Glu Ser Gln Cys Glu Gly Pro Glu 405 410 415 Lys Arg Glu Gly Lys Ala Glu Asp Arg Gly Gln Cys Asn His Val Arg 420 425 430 Ile Asn Gln Thr Val Thr Phe Trp Val Ser Leu Gln Ala Thr His Cys 435 440 445 Leu Pro Glu Pro His Leu Leu Arg Leu Arg Ala Leu Gly Phe Ser Glu 450 455 460 Glu Leu Ile Val Glu Leu His Thr Leu Cys Asp Cys Asn Cys Ser Asp 465 470 475 480 Thr Gln Pro Gln Ala Pro His Cys Ser Asp Gly Gln Gly His Leu Gln 485 490 495 Cys Gly Val Cys Arg Asp Cys Ala Glu Cys Gly Ala Phe Arg Thr Gly 500 505 510 Pro Leu Ala Thr Asn Cys Ser Thr Ala Cys Ala His Thr Asn Val Thr 515 520 525 Leu Ala Leu Ala Pro Ile Leu Asp Asp Gly Trp Cys Lys Glu Arg Thr 530 535 540 Leu Asp Asn Gln Leu Phe Phe Phe Leu Val Glu Asp Asp Ala Arg Gly 545 550 555 560 Thr Val Val Leu Arg Val Arg Pro Gln Glu Lys Gly Ala Asp His Thr 565 570 575 Gln Ala Ile Val Leu Gly Cys Val Gly Gly Ile Val Ala Val Gly Leu 580 585 590 Gly Leu Val Leu Ala Tyr Arg Leu Ser Val Glu Ile Tyr Asp Arg Arg 595 600 605 Glu Tyr Ser Arg Phe Glu Lys Glu Gln Gln Gln Leu Asn Trp Lys Gln 610 615 620 Asp Ser Asn Pro Leu Tyr Lys Ser Ala Ile Thr Thr Thr Ile Asn Pro 625 630 635 640 Arg Phe Gln Glu Ala Asp Ser Pro Thr Leu 645 650 <210> 5 <211> 382 <212> PRT <213> Homo sapiens <400> 5 Met Asp Phe Gly Leu Ala Leu Leu Leu Ala Gly Leu Leu Gly Leu Leu 1 5 10 15 Leu Gly Gln Ser Leu Gln Val Lys Pro Leu Gln Val Glu Pro Pro Glu 20 25 30 Pro Val Val Ala Val Ala Leu Gly Ala Ser Arg Gln Leu Thr Cys Arg 35 40 45 Leu Ala Cys Ala Asp Arg Gly Ala Ser Val Gln Trp Arg Gly Leu Asp 50 55 60 Thr Ser Leu Gly Ala Val Gln Ser Asp Thr Gly Arg Ser Val Leu Thr 65 70 75 80 Val Arg Asn Ala Ser Leu Ser Ala Ala Gly Thr Arg Val Cys Val Gly 85 90 95 Ser Cys Gly Gly Arg Thr Phe Gln His Thr Val Gln Leu Leu Val Tyr 100 105 110 Ala Phe Pro Asp Gln Leu Thr Val Ser Pro Ala Ala Leu Val Pro Gly 115 120 125 Asp Pro Glu Val Ala Cys Thr Ala His Lys Val Thr Pro Val Asp Pro 130 135 140 Asn Ala Leu Ser Phe Ser Leu Leu Val Gly Gly Gln Glu Leu Glu Gly 145 150 155 160 Ala Gln Ala Leu Gly Pro Glu Val Gln Glu Glu Glu Glu Glu Pro Gln 165 170 175 Gly Asp Glu Asp Val Leu Phe Arg Val Thr Glu Arg Trp Arg Leu Pro 180 185 190 Pro Leu Gly Thr Pro Val Pro Pro Ala Leu Tyr Cys Gln Ala Thr Met 195 200 205 Arg Leu Pro Gly Leu Glu Leu Ser His Arg Gln Ala Ile Pro Val Leu 210 215 220 His Ser Pro Thr Ser Pro Glu Pro Pro Asp Thr Thr Ser Pro Glu Ser 225 230 235 240 Pro Asp Thr Thr Ser Pro Glu Ser Pro Asp Thr Thr Ser Gln Glu Pro 245 250 255 Pro Asp Thr Thr Ser Pro Glu Pro Pro Asp Lys Thr Ser Pro Glu Pro 260 265 270 Ala Pro Gln Gln Gly Ser Thr His Thr Pro Arg Ser Pro Gly Ser Thr 275 280 285 Arg Thr Arg Arg Pro Glu Ile Ser Gln Ala Gly Pro Thr Gln Gly Glu 290 295 300 Val Ile Pro Thr Gly Ser Ser Lys Pro Ala Gly Asp Gln Leu Pro Ala 305 310 315 320 Ala Leu Trp Thr Ser Ser Ala Val Leu Gly Leu Leu Leu Leu Ala Leu 325 330 335 Pro Thr Tyr His Leu Trp Lys Arg Cys Arg His Leu Ala Glu Asp Asp 340 345 350 Thr His Pro Pro Ala Ser Leu Arg Leu Leu Pro Gln Val Ser Ala Trp 355 360 365 Ala Gly Leu Arg Gly Thr Gly Gln Val Gly Ile Ser Pro Ser 370 375 380 <210> 6 <211> 739 <212> PRT <213> humans <400> 6 Met Pro Gly Lys Met Val Val Ile Leu Gly Ala Ser Asn Ile Leu Trp 1 5 10 15 Ile Met Phe Ala Ala Ser Gln Ala Phe Lys Ile Glu Thr Thr Pro Glu 20 25 30 Ser Arg Tyr Leu Ala Gln Ile Gly Asp Ser Val Ser Leu Thr Cys Ser 35 40 45 Thr Thr Gly Cys Glu Ser Pro Phe Phe Ser Trp Arg Thr Gln Ile Asp 50 55 60 Ser Pro Leu Asn Gly Lys Val Thr Asn Glu Gly Thr Thr Ser Thr Leu 65 70 75 80 Thr Met Asn Pro Val Ser Phe Gly Asn Glu His Ser Tyr Leu Cys Thr 85 90 95 Ala Thr Cys Glu Ser Arg Lys Leu Glu Lys Gly Ile Gln Val Glu Ile 100 105 110 Tyr Ser Phe Pro Lys Asp Pro Glu Ile His Leu Ser Gly Pro Leu Glu 115 120 125 Ala Gly Lys Pro Ile Thr Val Lys Cys Ser Val Ala Asp Val Tyr Pro 130 135 140 Phe Asp Arg Leu Glu Ile Asp Leu Leu Lys Gly Asp His Leu Met Lys 145 150 155 160 Ser Gln Glu Phe Leu Glu Asp Ala Asp Arg Lys Ser Leu Glu Thr Lys 165 170 175 Ser Leu Glu Val Thr Phe Thr Pro Val Ile Glu Asp Ile Gly Lys Val 180 185 190 Leu Val Cys Arg Ala Lys Leu His Ile Asp Glu Met Asp Ser Val Pro 195 200 205 Thr Val Arg Gln Ala Val Lys Glu Leu Gln Val Tyr Ile Ser Pro Lys 210 215 220 Asn Thr Val Ile Ser Val Asn Pro Ser Thr Lys Leu Gln Glu Gly Gly 225 230 235 240 Ser Val Thr Met Thr Cys Ser Ser Glu Gly Leu Pro Ala Pro Glu Ile 245 250 255 Phe Trp Ser Lys Lys Leu Asp Asn Gly Asn Leu Gln His Leu Ser Gly 260 265 270 Asn Ala Thr Leu Thr Leu Ile Ala Met Arg Met Glu Asp Ser Gly Ile 275 280 285 Tyr Val Cys Glu Gly Val Asn Leu Ile Gly Lys Asn Arg Lys Glu Val 290 295 300 Glu Leu Ile Val Gln Glu Lys Pro Phe Thr Val Glu Ile Ser Pro Gly 305 310 315 320 Pro Arg Ile Ala Ala Gln Ile Gly Asp Ser Val Met Leu Thr Cys Ser 325 330 335 Val Met Gly Cys Glu Ser Pro Ser Phe Ser Trp Arg Thr Gln Ile Asp 340 345 350 Ser Pro Leu Ser Gly Lys Val Arg Ser Glu Gly Thr Asn Ser Thr Leu 355 360 365 Thr Leu Ser Pro Val Ser Phe Glu Asn Glu His Ser Tyr Leu Cys Thr 370 375 380 Val Thr Cys Gly His Lys Lys Leu Glu Lys Gly Ile Gln Val Glu Leu 385 390 395 400 Tyr Ser Phe Pro Arg Asp Pro Glu Ile Glu Met Ser Gly Gly Leu Val 405 410 415 Asn Gly Ser Ser Val Thr Val Ser Cys Lys Val Pro Ser Val Tyr Pro 420 425 430 Leu Asp Arg Leu Glu Ile Glu Leu Leu Lys Gly Glu Thr Ile Leu Glu 435 440 445 Asn Ile Glu Phe Leu Glu Asp Thr Asp Met Lys Ser Leu Glu Asn Lys 450 455 460 Ser Leu Glu Met Thr Phe Ile Pro Thr Ile Glu Asp Thr Gly Lys Ala 465 470 475 480 Leu Val Cys Gln Ala Lys Leu His Ile Asp Asp Met Glu Phe Glu Pro 485 490 495 Lys Gln Arg Gln Ser Thr Gln Thr Leu Tyr Val Asn Val Ala Pro Arg 500 505 510 Asp Thr Thr Val Leu Val Ser Pro Ser Ser Ile Leu Glu Glu Gly Ser 515 520 525 Ser Val Asn Met Thr Cys Leu Ser Gln Gly Phe Pro Ala Pro Lys Ile 530 535 540 Leu Trp Ser Arg Gln Leu Pro Asn Gly Glu Leu Gln Pro Leu Ser Glu 545 550 555 560 Asn Ala Thr Leu Thr Leu Ile Ser Thr Lys Met Glu Asp Ser Gly Val 565 570 575 Tyr Leu Cys Glu Gly Ile Asn Gln Ala Gly Arg Ser Arg Lys Glu Val 580 585 590 Glu Leu Ile Ile Gln Val Thr Pro Lys Asp Ile Lys Leu Thr Ala Phe 595 600 605 Pro Ser Glu Ser Val Lys Glu Gly Asp Thr Val Ile Ile Ser Cys Thr 610 615 620 Cys Gly Asn Val Pro Glu Thr Trp Ile Ile Leu Lys Lys Lys Ala Glu 625 630 635 640 Thr Gly Asp Thr Val Leu Lys Ser Ile Asp Gly Ala Tyr Thr Ile Arg 645 650 655 Lys Ala Gln Leu Lys Asp Ala Gly Val Tyr Glu Cys Glu Ser Lys Asn 660 665 670 Lys Val Gly Ser Gln Leu Arg Ser Leu Thr Leu Asp Val Gln Gly Arg 675 680 685 Glu Asn Asn Lys Asp Tyr Phe Ser Pro Glu Leu Leu Val Leu Tyr Phe 690 695 700 Ala Ser Ser Leu Ile Ile Pro Ala Ile Gly Met Ile Ile Tyr Phe Ala 705 710 715 720 Arg Lys Ala Asn Met Lys Gly Ser Tyr Ser Leu Val Glu Ala Gln Lys 725 730 735 Ser Lys Val <210> 7 <211> 42 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <220> <221> MOD_RES <222> (1)..(1) <223> Characterized by N-terminal biotin with a trioxane-succinic acid (Ttds) linker. <220> <221> MOD_RES <222> (42)..(42) <223> amidation <400> 7 Cys Ser Phe Asn Met Thr Thr Glu Leu Arg Asp Lys Lys Gln Lys Val 1 5 10 15 His Ala Leu Phe Tyr Lys Leu Asp Ile Val Pro Ile Glu Asp Asn Thr 20 25 30 Ser Ser Ser Glu Tyr Arg Leu Ile Asn Cys 35 40 <210> 8 <211> 42 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <220> <221> MOD_RES <222> (1)..(1) <223> Characterized by N-terminal biotin with a trioxane-succinic acid (Ttds) linker. <220> <221> MOD_RES <222> (42)..(42) <223> amidation <400> 8 Cys Ser Phe Asn Met Thr Thr Glu Leu Arg Asp Lys Lys Gln Lys Val 1 5 10 15 His Ala Leu Phe Tyr Lys Ala Ala Ala Ala Pro Ile Glu Asp Asn Thr 20 25 30 Ser Ser Ser Glu Tyr Arg Leu Ile Asn Cys 35 40 <210> 9 <400> 9 000 <210> 10 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 10 Glu Val Gln Leu Gln Gln Ser Val Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Lys Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu His Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Ser Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 110 <210> 11 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 11 Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly 1 5 10 15 Asp Thr Val Ser Ile Thr Cys His Ala Ser Gln Gly Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Arg Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 65 70 75 80 Glu Asp Phe Ala Asp Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Thr Leu Glu Ile Lys 100 105 <210> 12 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 12 Asn Thr Tyr Met His 1 5 <210> 13 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 13 Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro 1 5 10 <210> 14 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 14 Val Asp Ser 1 <210> 15 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 15 His Ala Ser Gln Gly Ile Ser Asp Asn Ile Gly 1 5 10 <210> 16 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 16 His Gly Thr Asn Leu Glu Asp 1 5 <210> 17 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 17 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 18 <400> 18 000 <210> 19 <400> 19 000 <210> 20 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 20 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Asp Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> twenty one <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <220> <221> VARIANT <222> (23)..(23) <223> K to T <220> <221> VARIANT <222> (24)..(24) <223> A to T <220> <221> VARIANT <222> (38)..(38) <223> R to K <220> <221> VARIANT <222> (40)..(40) <223> A to R <220> <221> VARIANT <222> (48)..(48) <223> M to I <220> <221> VARIANT <222> (67)..(67) <223> R to K <220> <221> VARIANT <222> (68)..(68) <223> V to A <220> <221> VARIANT <222> (77)..(77) <223> S to N <220> <221> VARIANT <222> (81)..(81) <223> M to L <220> <221> VARIANT <222> (97)..(97) <223> A to Y <220> <221> VARIANT <222> (98)..(98) <223> R to Y <400> 21 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Asp Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 22 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 22 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 23 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 23 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 24 <400> 24 000 <210> 25 <211> 108 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 25 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Gly Ile Ser Asp Asn 20 25 30 Ile Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 <210> 26 <211> 108 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <220> <221> VARIANT <222> (36)..(36) <223> Y to L <220> <221> VARIANT <222> (43)..(43) <223> A to S <220> <221> VARIANT <222> (44)..(44) <223> P to F <220> <221> VARIANT <222> (46)..(46) <223> L to G <220> <221> VARIANT <222> (69)..(69) <223> T to A <220> <221> VARIANT <222> (71)..(71) <223> F to Y <400> 26 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Gly Ile Ser Asp Asn 20 25 30 Ile Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 <210> 27 <211> 108 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 27 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Gly Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Ala Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 <210> 28 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 28 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Gly Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 29 <400> 29 000 <210> 30 <400> 30 000 <210> 31 <400> 31 000 <210> 32 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 32 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 33 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 33 Arg Ile Asp Pro Ala Asn Gly His Thr Glu Tyr Ala Pro Lys Phe Gln 1 5 10 15 Gly <210> 34 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 34 Val Asp Ser 1 <210> 35 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 35 His Ala Ser Gln Gly Ile Ser Asp Asn Ile Gly 1 5 10 <210> 36 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 36 His Gly Thr Asn Leu Glu Asp 1 5 <210> 37 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 37 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 38 <400> 38 000 <210> 39 <400> 39 000 <210> 40 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 40 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Lys His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Ala Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 41 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 41 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Glu Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 42 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 42 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 43 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 43 Arg Ile Asp Pro Ala Asn Lys His Thr Glu Tyr Ala Pro Lys Phe Leu 1 5 10 15 Gly <210> 44 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 44 Val Ala Ser 1 <210> 45 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 45 His Ala Ser Gln Glu Ile Ser Asp Asn Ile Gly 1 5 10 <210> 46 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 46 His Gly Thr Asn Leu Glu Asp 1 5 <210> 47 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 47 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 48 <400> 48 000 <210> 49 <400> 49 000 <210> 50 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 50 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Arg Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Ser Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Gln Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 51 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 51 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asp Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 52 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 52 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 53 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 53 Arg Ile Asp Pro Ala Arg Gly His Thr Glu Tyr Ala Pro Lys Phe Ser 1 5 10 15 Gly <210> 54 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 54 Val Asp Gln 1 <210> 55 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 55 His Ala Ser Gln Asp Ile Ser Asp Asn Ile Gly 1 5 10 <210> 56 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 56 His Gly Thr Asn Leu Glu Asp 1 5 <210> 57 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 57 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 58 <400> 58 000 <210> 59 <400> 59 000 <210> 60 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 60 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Arg Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Glu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Ala Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 61 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 61 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asp Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 62 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 62 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 63 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 63 Arg Ile Asp Pro Ala Arg Gly His Thr Glu Tyr Ala Pro Lys Phe Glu 1 5 10 15 Gly <210> 64 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 64 Val Ala Ser 1 <210> 65 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 65 His Ala Ser Gln Asp Ile Ser Asp Asn Ile Gly 1 5 10 <210> 66 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 66 His Gly Thr Asn Leu Glu Asp 1 5 <210> 67 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 67 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 68 <400> 68 000 <210> 69 <400> 69 000 <210> 70 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 70 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 71 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 71 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asp Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 72 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 72 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 73 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 73 Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe Leu 1 5 10 15 Gly <210> 74 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 74 Val Asp Val 1 <210> 75 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 75 His Ala Ser Gln Asp Ile Ser Asp Asn Ile Gly 1 5 10 <210> 76 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 76 His Gly Thr Asn Leu Glu Asp 1 5 <210> 77 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 77 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 78 <400> 78 000 <210> 79 <400> 79 000 <210> 80 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 80 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Gly Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Ile Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Ala Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 81 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 81 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Glu Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 82 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 82 Gly Phe Asn Ile Lys Asn Thr Tyr Met His 1 5 10 <210> 83 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 83 Arg Ile Asp Pro Ala Gly Gly His Thr Glu Tyr Ala Pro Lys Phe Ile 1 5 10 15 Gly <210> 84 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 84 Val Ala Ser 1 <210> 85 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 85 His Ala Ser Gln Glu Ile Ser Asp Asn Ile Gly 1 5 10 <210> 86 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 86 His Gly Thr Asn Leu Glu Asp 1 5 <210> 87 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 87 Val Gln Tyr Ala Gln Phe Pro Trp Thr 1 5 <210> 88 <400> 88 000 <210> 89 <400> 89 000 <210> 90 <211> 442 <212> PRT <213> Artificial sequence <220> <223> Synthetic peptides <400> 90 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 340 345 350 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 91 <211> 441 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 91 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 340 345 350 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 92 <211> 442 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 92 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 93 <211> 441 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 93 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 94 <211> 442 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 94 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 95 <211> 441 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 95 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 96 <211> 442 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 96 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 97 <211> 441 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 97 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 98 <211> 442 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 98 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 99 <211> 441 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 99 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asn Thr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Lys Gly His Thr Glu Tyr Ala Pro Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Tyr Tyr Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 100 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 100 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asp Ile Ser Asp Asn 20 25 30 Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Leu Leu Ile 35 40 45 Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210

Claims

1. An anti-human α4β7 monoclonal antibody comprising (i) a VH chain region containing three CDRs; and (ii) a VL chain region containing three CDRs, wherein: VH CDR#1 is GFNIKNTYMH (SEQ ID NO:72); VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO:73); VH CDR#3 is VDV (SEQ ID NO:74); VL CDR#1 is HASQDISDNIG (SEQ ID NO:75); VL CDR#2 is HGTNLED (SEQ ID NO:76); and VL CDR#3 is VQYAQFPWT (SEQ ID NO:77).

2. The anti-human α4β7 monoclonal antibody according to claim 1, comprising: VH Chain Section: AND VL Chain Zone: DIQMTQSPSSSLSASVGDRVTITCHASQDISDNIGWLQQKPGKSFKLLIYHGTNLEDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKVEIK (SEQ ID NO:71).

3. The anti-human α4β7 monoclonal antibody according to claim 2 is IgG.

4. The anti-human α4β7 monoclonal antibody according to claim 3, comprising the κ light chain constant region.

5. The anti-human α4β7 monoclonal antibody according to claim 4, wherein it is IgG1.

6. The anti-human α4β7 monoclonal antibody according to claim 5, comprising a variant CH3 domain having amino acid substitutions D356E and L358M.

7. The anti-human α4β7 monoclonal antibody according to claim 1, comprising a heavy chain having the amino acid sequence of SEQ ID NO:92 or SEQ ID NO:93 and a light chain having the amino acid sequence of SEQ ID NO:

100.

8. The anti-human α4β7 monoclonal antibody according to claim 1, which is an IgG1 antibody comprising a heavy chain and a light chain, wherein each of the heavy chains consists of the amino acid sequence of SEQ ID NO:92 and each of the light chains consists of the amino acid sequence of SEQ ID NO:

100.

9. The anti-human α4β7 monoclonal antibody according to claim 1, which is an IgG1 antibody comprising a heavy chain and a light chain, wherein each of the heavy chains consists of the amino acid sequence of SEQ ID NO:93 and each of the light chains consists of the amino acid sequence of SEQ ID NO:

100.

10. A polynucleotide comprising a nucleotide sequence encoding an anti-human α4β7 monoclonal antibody, wherein the antibody comprises (i) a VH region comprising three CDRs; and (ii) a VL region comprising three CDRs, wherein: VH CDR#1 is GFNIKNTYMH (SEQ ID NO:72); VH CDR#2 is RIDPAKGHTEYAPKFLG (SEQ ID NO:73); VH CDR#3 is VDV (SEQ ID NO:74); VL CDR#1 is HASQDISDNIG (SEQ ID NO:75); VL CDR#2 is HGTNLED (SEQ ID NO:76); and VL CDR#3 is VQYAQFPWT (SEQ ID NO:77).

11. An expression vector comprising the polynucleotide of claim 10.

12. A eukaryotic host cell transfected with the expression vector of claim 11.

13. The eukaryotic host cell according to claim 12, wherein it is a mammalian host cell.

14. A method for producing an anti-human α4β7 monoclonal antibody, comprising: (a) culturing the eukaryotic host cell of claim 13 and (b) recovering the anti-human α4β7 monoclonal antibody.

15. A pharmaceutical composition comprising the anti-human α4β7 monoclonal antibody according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Portable radio system for dual programmable push-to-talk buttons and method for the same

    US10251030B2

  • Engineering Fc antibody regions to confer effector function

    US20060134709A1

  • Antibody variants

    US20070280931A1

  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

    US7217797B2

  • Automatic music-playing attachment for pianos.

    US913242A